AGREEMENT AND PLAN OF MERGER between APRIA HEALTHCARE, INC. APCO, INC. and CORAM, INC. Dated as of October 13, 2007
EXHIBIT 2.1
between
APRIA HEALTHCARE, INC.
APCO, INC.
and
CORAM, INC.
Dated as of October 13, 2007
TABLE OF CONTENTS
Page | ||||||||
ARTICLE I DEFINITIONS | 1 | |||||||
Section 1.1 | Certain Defined Terms | 1 | ||||||
Section 1.2 | Table of Definitions | 7 | ||||||
ARTICLE II THE MERGER | 10 | |||||||
Section 2.1 | The Merger | 10 | ||||||
Section 2.2 | Closing; Effective Time | 10 | ||||||
Section 2.3 | Effects of the Merger | 10 | ||||||
Section 2.4 | Certificate of Incorporation and Bylaws | 10 | ||||||
Section 2.5 | Directors; Officers | 11 | ||||||
Section 2.6 | Subsequent Actions | 11 | ||||||
Section 2.7 | Conversion of Stock | 11 | ||||||
Section 2.8 | Dissenting Shares | 12 | ||||||
Section 2.9 | Options | 12 | ||||||
Section 2.10 | Payment for Shares. | 12 | ||||||
Section 2.11 | Withholding Rights | 14 | ||||||
ARTICLE III REPRESENTATIONS AND WARRANTIES OF THE COMPANY | 14 | |||||||
Section 3.1 | Organization and Qualification | 14 | ||||||
Section 3.2 | Authority | 15 | ||||||
Section 3.3 | No Conflict; Required Filings and Consents | 15 | ||||||
Section 3.4 | Capitalization | 16 | ||||||
Section 3.5 | Equity Interests | 17 | ||||||
Section 3.6 | Financial Statements; No Undisclosed Liabilities | 18 | ||||||
Section 3.7 | Accounts Receivable | 19 | ||||||
Section 3.8 | Customers and Suppliers | 19 | ||||||
Section 3.9 | Absence of Certain Changes or Events | 19 | ||||||
Section 3.10 | Compliance with Law; Permits | 20 | ||||||
Section 3.11 | Litigation | 20 | ||||||
Section 3.12 | Employee Benefit Plans | 21 | ||||||
Section 3.13 | Labor and Employment Matters | 23 | ||||||
Section 3.14 | Assets | 24 | ||||||
Section 3.15 | Real Property | 25 | ||||||
Section 3.16 | Intellectual Property | 25 | ||||||
Section 3.17 | Taxes | 26 | ||||||
Section 3.18 | Environmental Matters | 28 | ||||||
Section 3.19 | Material Contracts | 29 | ||||||
Section 3.20 | Affiliate Interests and Transactions | 31 | ||||||
Section 3.21 | Insurance. | 32 | ||||||
Section 3.22 | Brokers | 32 | ||||||
Section 3.23 | Health Care Matters | 32 | ||||||
Section 3.24 | Inspections and Investigations | 33 |
i
TABLE OF CONTENTS
(Continued)
(Continued)
Page | ||||||||
Section 3.25 | Rates and Reimbursements | 34 | ||||||
Section 3.26 | Regulatory Matters. | 34 | ||||||
Section 3.27 | Inventory | 37 | ||||||
ARTICLE IV REPRESENTATIONS AND WARRANTIES OF THE ACQUIROR AND MERGER SUB | 37 | |||||||
Section 4.1 | Organization | 37 | ||||||
Section 4.2 | Authority | 37 | ||||||
Section 4.3 | No Conflict; Required Filings and Consents | 37 | ||||||
Section 4.4 | Financing | 38 | ||||||
Section 4.5 | Brokers | 38 | ||||||
ARTICLE V COVENANTS | 38 | |||||||
Section 5.1 | Conduct of Business Prior to the Closing | 38 | ||||||
Section 5.2 | Access to Information | 41 | ||||||
Section 5.3 | Exclusivity | 41 | ||||||
Section 5.4 | Notification of Certain Matters | 42 | ||||||
Section 5.5 | Takeover Statutes | 43 | ||||||
Section 5.6 | Stock Option Plans | 43 | ||||||
Section 5.7 | Confidentiality | 43 | ||||||
Section 5.8 | Reasonable Best Efforts. | 43 | ||||||
Section 5.9 | Public Announcements | 45 | ||||||
Section 5.10 | Financing. | 45 | ||||||
Section 5.11 | Employees. | 46 | ||||||
Section 5.12 | Indemnification and Insurance. | 48 | ||||||
Section 5.13 | Section 280G Stockholder Approval. | 49 | ||||||
ARTICLE VI CONDITIONS TO CLOSING | 49 | |||||||
Section 6.1 | General Conditions | 49 | ||||||
Section 6.2 | Conditions to Obligations of the Company | 50 | ||||||
Section 6.3 | Conditions to Obligations of the Acquiror and Merger Sub | 50 | ||||||
ARTICLE VII SURVIVAL | 51 | |||||||
Section 7.1 | Survival of Representations, Warranties and Covenants | 51 | ||||||
ARTICLE VIII TERMINATION | 52 | |||||||
Section 8.1 | Termination | 52 | ||||||
Section 8.2 | Effect of Termination | 53 | ||||||
ARTICLE IX GENERAL PROVISIONS | 53 | |||||||
Section 9.1 | Fees and Expenses | 53 |
ii
TABLE OF CONTENTS
(Continued)
(Continued)
Page | ||||||||
Section 9.2 | Amendment and Modification | 53 | ||||||
Section 9.3 | Extension | 53 | ||||||
Section 9.4 | Waiver | 53 | ||||||
Section 9.5 | Notices | 54 | ||||||
Section 9.6 | Interpretation | 55 | ||||||
Section 9.7 | Entire Agreement | 55 | ||||||
Section 9.8 | No Third-Party Beneficiaries | 55 | ||||||
Section 9.9 | Governing Law | 55 | ||||||
Section 9.10 | Enforcement | 55 | ||||||
Section 9.11 | Assignment; Successors | 55 | ||||||
Section 9.12 | Currency | 56 | ||||||
Section 9.13 | Severability | 56 | ||||||
Section 9.14 | Waiver of Jury Trial | 56 | ||||||
Section 9.15 | Counterparts | 56 | ||||||
Section 9.16 | Facsimile Signature | 56 | ||||||
Section 9.17 | Time of Essence | 56 | ||||||
Section 9.18 | No Presumption Against Drafting Party | 56 |
iii
EXHIBIT INDEX
Exhibit A
|
Form of Certificate of Merger | |
Exhibit B
|
Officers of the Surviving Corporation |
iv
THIS AGREEMENT AND PLAN OF MERGER, dated as of October 13, 2007 (this “Agreement”), is
between Apria Healthcare, Inc., a Delaware corporation (the “Acquiror”), APCO, Inc., a
Delaware corporation and a wholly owned subsidiary of the Acquiror (“Merger Sub”), and
Coram, Inc., a Delaware corporation (the “Company”).
RECITALS
A. The Company is engaged in the business of providing home infusion pharmacy services and
specialty pharmacy services to patients with acute or chronic conditions (the “Business”).
B. The Boards of Directors of each of the Acquiror, the Company and Merger Sub have (i)
determined that the merger of Merger Sub with and into the Company (the “Merger”) would be
advisable and fair to, and in the best interests of, their respective stockholders and (ii)
approved the Merger upon the terms and subject to the conditions set forth in this Agreement
pursuant to the General Corporation Law of the State of Delaware (the “DGCL”).
C. The Stockholders hold all of the outstanding voting power of the Company entitled to vote
on the adoption of this Agreement and the approval of the Merger.
D. Concurrently with the execution and delivery of this Agreement, as an inducement to the
Acquiror’s and Merger Sub’s willingness to enter into this Agreement and incur the obligations set
forth herein, each of the stockholders of the Company (collectively, the “Stockholders”)
has executed letter agreements committing to execute and deliver written consents adopting this
Agreement and approving the Merger (collectively, such Stockholders’ approvals, the “Company
Stockholder Approval”).
AGREEMENT
NOW, THEREFORE, in consideration of the foregoing and the mutual covenants and agreements
herein contained, and intending to be legally bound hereby, the parties agree as follows:
ARTICLE I
DEFINITIONS
DEFINITIONS
Section 1.1 Certain Defined Terms. For purposes of this Agreement:
“Accounts Receivable” means all accounts, both billed and unbilled, including
retainage and work in progress, owned or acquired by the Company and each of the Company Affiliates
including accounts receivable, notes and notes receivable, other receivables and book debts.
1
“Acquisition Proposal” means any offer or proposal for, or any indication of interest
in, any of the following (other than the Merger): (a) any direct or indirect acquisition or
purchase of all or any portion of the capital stock of the Company or any of the Company Affiliates
or assets of the Company or any of the Company Affiliates (other than inventory to be sold in the
ordinary course of business consistent with past practice), (b) any merger, consolidation or other
business combination relating to the Company or any of the Company Affiliates or (c) any
recapitalization, reorganization or any other extraordinary business transaction involving or
otherwise relating to the Company or any of the Company Affiliates.
“Action” means any claim, action, suit, inquiry, proceeding, audit or investigation by
or before any Governmental Authority, or any other arbitration, mediation or similar proceeding.
“Affiliate” means, with respect to any Person, any other Person that directly, or
indirectly through one or more intermediaries, controls, is controlled by, or is under common
control with, such first Person. Notwithstanding the foregoing, no “portfolio company” of any
Stockholder shall be deemed to be an Affiliate of the Company or such Stockholder.
“Business Day” means any day that is not a Saturday, a Sunday or other day on which
banks are required or authorized by Law to be closed in the State of Delaware and/or the City of
New York.
“Company Affiliates” means all Subsidiaries of the Company and the entities set forth
on Section 1.1(a) of the Disclosure Letter.
“Company Common Stock” means the common stock, par value $0.01 per share, of the
Company.
“Company Preferred Stock” means the Series A Preferred Stock, par value $0.01 per
share, of the Company.
“Contract” means any contract, agreement, arrangement or understanding, whether
written or oral and whether express or implied.
“control,” including the terms “controlled by” and “under common control
with,” means the possession, directly or indirectly, of the power to direct or cause the
direction of the management and policies of a Person, whether through the ownership of voting
securities, as trustee or executor, as general partner or managing member, by Contract or
otherwise, including the ownership, directly or indirectly, of securities having the power to elect
a majority of the board of directors or similar body governing the affairs of such Person.
“Controlled Group Liability” means any material liability (a) under Title IV
of ERISA, (b) under Section 302 of ERISA, (c) under Sections 412 and 4971 of the Code or (d) as a
result of a failure to comply with the continuation coverage requirements of Section 601 et seq. of
ERISA and Section 4980B of the Code, other than such liabilities that arise out of, or relate to,
the Plans listed in Section 3.12(a) of the Disclosure Letter.
2
“Encumbrance” means any charge, claim, limitation, condition, equitable interest,
mortgage, lien, option, pledge, security interest, easement, encroachment, right of first refusal,
adverse claim or restriction of any kind, including any restriction on or transfer or other
assignment, as security or otherwise, of or relating to use, quiet enjoyment, voting, transfer,
receipt of income or exercise of any other attribute of ownership.
“Environmental Laws” means: any Laws of any Governmental Authority relating to (i)
releases or threatened releases of Hazardous Substances or materials containing Hazardous
Substances; (ii) the presence, production, distribution, testing, discharge, control, cleanup,
manufacture, handling, transport, use, treatment, storage or disposal of Hazardous Substances or
materials containing Hazardous Substances; or (iii) pollution or protection of the environment,
health, safety or natural resources.
“Environmental Permits” means all Permits under any Environmental Law.
“ERISA Affiliate” means any trade or business, whether or not incorporated, under
common control with the Company or any of the Company Affiliates and that, together with the
Company or any of the Company Affiliates, is treated as a single employer within the meaning of
Section 414(b), (c), (m) or (o) of the Code.
“Exchange Act” means the Securities Exchange Act of 1934, as amended, and the
regulations promulgated thereunder.
“Federal Controlled Substances Act” means the Federal Controlled Substances Act, 21
U.S.C. §§ 801 et seq.
“Federal Food, Drug and Cosmetic Act” means the Federal Food, Drug and Cosmetic Act,
21 U.S.C. §§ 301 et seq.
“Fully Diluted Shares” means the aggregate number of Common Shares (other than Shares
to be cancelled in accordance with Sections 2.7(c) and 2.7(d)) and Common Share equivalents on an
as converted basis (including the Company Preferred Stock, options, warrants and other interests
convertible into or exchangeable for Common Shares) outstanding immediately prior to the Effective
Time, including for purposes of this computation the aggregate number of Common Shares issuable
upon the exercise in full of all Options converted into the right to receive cash pursuant to
Section 2.9.
“GAAP” means United States generally accepted accounting principles and practices.
“Government Program” means any Medicare, Medicaid, CHAMPUS, Veterans Administration or
TriCare program and such other similar federal, state or local reimbursement or governmental
programs for which the Company is eligible and in which the Company participates.
“Governmental Authority” means any United States or Canadian federal, national, state,
provincial, local or similar government, governmental, regulatory or administrative
3
authority,
branch, agency or commission or any court, tribunal, or arbitral or judicial body (including any
grand jury).
“Hazardous Substances” means: (a) those substances defined in or regulated under the
Hazardous Materials Transportation Act, the Resource Conservation and Recovery Act, the
Comprehensive Environmental Response, Compensation and Liability Act (“CERCLA”), the Clean
Water Act, the Safe Drinking Water Act, the Atomic Energy Act, the Federal Insecticide, Fungicide,
and Rodenticide Act and the Clean Air Act, and their state counterparts, or any other Environmental
Law, as each may be amended from time to time, and all regulations thereunder; (b) petroleum and
petroleum products or by-products, including crude oil and any fractions thereof; (c) natural gas,
synthetic gas, and any mixtures thereof; (d) radioactive materials, mold, polychlorinated
biphenyls, asbestos and radon; (e) any other pollutant or contaminant; and (f) any substance,
material or waste regulated by any Governmental Authority pursuant to any Environmental Law.
“Health Care Law” means, all relevant laws of any Governmental Authority regulating
health services or payment, including, but not limited to, the federal Anti-Kickback Statute (42
U.S.C. § 1320a-7b(b)), the Xxxxx Law (42 U.S.C. § 1395nn), the Anti-Inducement Law (42 U.S.C. §
1320a-7a(a)(5)), the civil False Claims Act (31 U.S.C. § 3729 et seq.), the administrative False
Claims Law (42 U.S.C. § 1320a-7b(a)), the exclusion laws (42 U.S.C. § 1320a-7), the civil monetary
penalty laws (42 U.S.C. § 1320a-7a), the administrative simplification provisions of the Health
Insurance Portability and Accountability Act of 1996 (42 U.S.C. §§ 1320d-1320d-8), the Medicare
Prescription Drug, Improvement and Modernization Act of 2003, Medicare (Title XVIII of the Social
Security Act), Medicaid (Title XIX of the Social Security Act), the Food, Drug and Cosmetic Act (21
C.F.R. §§ 301 et seq.), the Prescription Drug Marketing Act of 1987, the Deficit Reduction Act of
2005, the regulations promulgated pursuant to such laws, and any other law, regulation, guidance
document, manual provision, program memorandum, opinion letter, or other issuance of any
Governmental Authority which regulates kickbacks, patient or program charges, recordkeeping, claims
process, documentation requirements, medical necessity, referrals, the hiring of employees or
acquisition of services or supplies from those who have been excluded from government health care
programs, quality, safety, privacy, security, pharmacy practice, licensure, accreditation or any
other aspect of providing health care.
“Health Care Permit” means any and all licenses, permits, authorizations, approvals,
franchises, registrations, accreditations, certificates of need, consents, supplier or provider
numbers, qualifications, operating authority, and/or any other permit or permission which are
material to or legally required for the operation of the Company’s business as currently conducted
or in connection with the Company’s ability to own, lease operate or manage any of its property, in each case that are issued or enforced by a
Governmental Authority with jurisdiction over any Health Care Law.
“Immediate Family” with respect to any specified Person, means such Person’s spouse,
parents, children and siblings, including adoptive relationships and relationships through
marriage, or any other relative of such Person that shares such Person’s home.
4
“Intellectual Property” means (a) all inventions (whether patentable or unpatentable
and whether or not reduced to practice), all improvements thereto, and all patents, patent
applications, and patent disclosures, together with all provisionals, reissuances, continuations,
continuations-in-part, divisions, revisions, extensions, and reexaminations thereof, (b) all
trademarks, service marks, trade dress, logos, brand names, trade names, domain names and corporate
names, together with all translations, adaptations, derivations, and combinations thereof, and all
applications, registrations, and renewals in connection therewith, (c) all copyrightable works, all
copyrights, any and all website content, and all applications, registrations, and renewals in
connection therewith, (d) all trade secrets and confidential business information (including
research and development, know-how, formulas, compositions, manufacturing and production processes
and techniques, technical data, designs, drawings, specifications, research records, records of
inventions, test information, customer and supplier lists, pricing and cost information, and
business and marketing plans and proposals and similar information), (e) all source code and object
code versions of computer software (including data and related documentation), (f) proprietary
clinical outcome tools, reports, and longitudinal databases, and (g) all other proprietary rights.
“knowledge” with respect to the Company means the actual knowledge of any of the
individuals set forth in Section 1.1(b) of the Disclosure Letter.
“Law” means any statute, law, ordinance, regulation, rule, code, executive order,
injunction, judgment, decree or order of any Governmental Authority.
“Leased Real Property” means all real property leased, subleased or licensed to the
Company or any of the Company Affiliates or which the Company or any of the Company Affiliates
otherwise has a right or option to use or occupy, together with all structures, facilities,
fixtures, pharmacy hoods, compounding equipment, systems, improvements and items of property
previously or hereafter located thereon, or attached or appurtenant thereto, and all easements,
rights and appurtenances relating to the foregoing.
“Liquidation Preference” means $54,000,000.
“Liquidation Preference Per Share” means the amount equal to (a) the Liquidation
Preference divided by (b) the aggregate number of shares of Company Preferred Stock outstanding
immediately prior to the Effective Time.
“Material Adverse Effect” means any event, change, circumstance, effect or state of
facts that is materially adverse to the business, operations, financial condition or results of
operations of the Company and the Company Affiliates, taken as a whole; provided,
that no event, change, circumstance, effect or state of facts shall be deemed (individually
or in the aggregate) to constitute, nor shall any of the foregoing be taken into account in
determining whether there has been, a Material Adverse Effect, to the extent that such event,
change, circumstance, effect or state of facts results from, arises out of, or relates to (i) a
general deterioration in the economy or in the economic conditions prevalent in the industry in
which the Company operates (except to the extent that the Company is affected materially
disproportionately relative to other Persons in the industry in which the Company operates), (ii)
any change in applicable Law, GAAP or accounting requirements or principles, (iii) any
5
change in
the Centers for Medicare and Medicaid Services’ reimbursement rates, (iv) the announcement or the
existence of, or compliance with, this Agreement or the announcement of the Merger or any of the
other transactions contemplated by this Agreement, (v) the failure of the Company to meet any
expected or projected financial or operating performance target (provided that the event, change,
circumstance, effect or state of facts giving rise to such failure may be considered in determining
whether a Material Adverse Effect has occurred) or (vi) the effect of any matter which is
specifically disclosed in the Disclosure Letter.
“Merger Consideration” means $350,000,000.00 minus the Transaction Expenses.
“Option” means each outstanding option to purchase Shares.
“ordinary course of business” or “ordinary course” or any similar phrase means
the ordinary course of the Business, consistent with past practice of the Company.
“Owned Real Property” means all real property owned by the Company or any of the
Company Affiliates, together with all structures, facilities, fixtures, systems, improvements and
items of property previously or hereafter located thereon, or attached or appurtenant thereto, and
all easements, rights and appurtenances relating to the foregoing.
“Per Share Merger Consideration” means the amount equal to (a) (x) the difference
between the Merger Consideration and the Liquidation Preference plus (y) aggregate amount that
would be paid to the Company in respect of all Options outstanding immediately prior to the
Effective Time if the holders thereof exercised such Options immediately prior to the Effective
Time, divided by (b) the number of Fully Diluted Shares.
“Permitted Encumbrances” means (a) liens for current taxes and assessments not yet
past due, (b) mechanics’, workmen’s, repairmen’s, warehousemen’s and carriers’ liens arising in the
ordinary course of business of the Company or such Company Affiliate consistent with past practice,
(c) any such matters of record, Encumbrances and other imperfections of title that do not,
individually or in the
aggregate, materially impair the continued ownership, use and operation of the assets to which
they relate in the business of the Company and the Company Affiliates as currently conducted and
(d) any Encumbrances with respect to the Amended and Restated Credit Agreement by and among the
Company, the Financial Institutions from time to time party thereto and Xxxxxxx Sachs Specialty
Lending Group, LP as administrative and collateral agent, dated as of June 7, 2006, as amended from
time to time.
“Person” means an individual, corporation, partnership, limited liability company,
limited liability partnership, syndicate, person, trust, association, organization or other entity,
including any Governmental Authority, and including any successor, by merger or otherwise, of any
of the foregoing.
“Private Program” means any non-governmental third party payor with which the Company
has a Contract to provide services and to receive payment therefor.
“Related Party” with respect to any specified Person, means: (a) any Affiliate of
such specified Person, or any director, executive officer, general partner or managing member of
6
such Affiliate; (b) any Person who serves or within the past five years has served as a director,
executive officer, partner, member or in a similar capacity of such specified Person; (c) any
Immediate Family member of a Person described in clause (b); or (d) any other Person who holds,
individually or together with any Affiliate of such other Person and any member(s) of such Person’s
Immediate Family, more than 5% of the outstanding voting equity or ownership interests of such
specified Person.
“Release” has the meaning set forth in Section 101(22) of CERCLA.
“Return” means any federal, state, provincial, district, municipal, county, local and
foreign return, declaration, report, statement, information statement and other document required
to be filed or filed with respect to Taxes, including any claims for refunds of Taxes and any
amendments or supplements of any of the foregoing.
“Subsidiary” means, with respect to any Person, any other Person controlled by such
first Person, directly or indirectly, through one or more intermediaries.
“Taxes” means: (a) all federal, state, local, foreign and other net income, gross
income, gross receipts, sales, use, ad valorem, transfer, franchise, profits, registration,
license, lease, service, service use, withholding, payroll, employment, excise, severance, stamp,
occupation, premium, property, windfall profits, customs, duties or other taxes, fees, assessments
or charges of any kind whatsoever, together with any interest and any penalties, additions to tax
or additional amounts with respect thereto; (b) any liability for payment of amounts described in
clause (a) whether as a result of transferee liability, of being a member of an affiliated,
consolidated, combined or unitary group for any period or otherwise through operation of law; and
(c) any liability for the payment of amounts described in clauses (a) or (b) as a result of any tax sharing, tax indemnity or tax allocation agreement or any
other express or implied agreement to indemnify any other Person.
“Transaction Expenses” means all fees and expenses payable by the Company and the
Company Affiliates in connection with the transactions contemplated by this Agreement, including
fees and expenses payable to all attorneys, accountants, financial advisors and other professionals
and bankers’, brokers’ or finders’ fees for persons not engaged by the Acquiror or Merger Sub.
Section 1.2 Table of Definitions. The following terms have the meanings set forth in the Sections referenced below:
Definition | Location | |
Accounts Receivable |
1.1 | |
Acquiror |
Preamble | |
Acquisition Proposal |
1.1 | |
Action |
1.1 | |
Affiliate |
1.1 | |
Agreement |
Preamble | |
AHG |
4.4 | |
Balance Sheet Date |
3.6(a) |
7
Definition | Location | |
Bonus Plan |
5.11(d) | |
Business |
Recitals | |
Business Day |
1.1 | |
CCA |
3.26(d) | |
CERCLA |
1.1 | |
Certificate of Merger |
2.2(b) | |
Certificates |
2.10(b) | |
CIA |
3.26(d) | |
Closing |
2.2(a) | |
Closing Date |
2.2(a) | |
Code |
3.12(b) | |
Common Shares |
2.7 | |
Company |
Preamble | |
Company Common Stock |
1.1 | |
Company Preferred Stock |
1.1 | |
Company Stockholder Approval |
Recitals | |
Confidentiality Agreement |
5.7 | |
Contract |
1.1 | |
control |
1.1 | |
Controlled Group Liability |
1.1 | |
Current Policies |
5.12(c) | |
DGCL |
Recitals | |
Disclosure Letter |
Article III | |
Dissenting Shares |
2.8 | |
Effective Time |
2.2(b) | |
Encumbrance |
1.1 | |
Environmental Laws |
1.1 | |
Environmental Permits |
1.1 | |
ERISA |
3.12(a)(i) | |
ERISA Affiliate |
1.1 | |
Exchange Act |
1.1 | |
Federal Controlled Substances Act |
1.1 | |
Federal Food, Drug and Cosmetic Act |
1.1 | |
Financial Statements |
3.6(a) | |
Fully Diluted Shares |
1.1 | |
GAAP |
1.1 | |
Government Program |
1.1 | |
Governmental Agreements |
3.26(d) | |
Governmental Authority |
1.1 | |
Hazardous Substances |
1.1 | |
Health Care Law |
1.1 | |
Health Care Permit |
1.1 | |
HSR Act |
3.3(b) | |
Immediate Family |
1.1 | |
Indemnified Party |
5.12(b) |
8
Definition | Location | |
Intellectual Property |
1.1 | |
Interim Financial Statements |
3.6(a) | |
IRS |
3.12(b) | |
knowledge |
1.1 | |
Law |
1.1 | |
Leased Real Property |
1.1 | |
Letter of Transmittal |
2.10(b) | |
Liquidation Preference |
1.1 | |
Liquidation Preference Per Share |
1.1 | |
Material Adverse Effect |
1.1 | |
Material Contracts |
3.19(a) | |
Merger |
Recitals | |
Merger Consideration |
1.1 | |
Merger Sub |
Preamble | |
Multiemployer Plan |
3.12(c) | |
Multiple Employer Plan |
3.12(c) | |
Option |
1.1 | |
ordinary course of business |
1.1 | |
Owned Real Property |
1.1 | |
Paying Agent |
2.10(a) | |
Paying Agent Agreement |
2.10(a) | |
Per Share Merger Consideration |
1.1 | |
Permits |
3.10(b) | |
Permitted Encumbrances |
1.1 | |
Person |
1.1 | |
Plans |
3.12(a) | |
Preferred Shares |
2.7 | |
Private Program |
1.1 | |
Programs |
3.23(c) | |
Related Party |
1.1 | |
Release |
1.1 | |
Remuneration |
3.26(f) | |
Representatives |
5.2 | |
Return |
1.1 | |
Rights |
3.26(b) | |
Shares |
2.7 | |
Stockholders |
Preamble | |
Subsidiary |
1.1 | |
Surviving Corporation |
2.1 | |
Taxes |
1.1 | |
Termination Date |
8.1(d) | |
Transaction Expenses |
1.1 |
9
ARTICLE II
THE MERGER
THE MERGER
Section 2.1 The Merger. Upon the terms and subject to the conditions of this Agreement, at the Effective Time and
in accordance with the DGCL, Merger Sub shall be merged with and into the Company pursuant to which
(i) the separate corporate existence of Merger Sub shall cease, (ii) the Company shall be the
surviving corporation in the Merger (the “Surviving Corporation”) and shall continue its
corporate existence under the laws of the State of Delaware as a wholly owned Subsidiary of the
Acquiror and (iii) all of the assets, properties, rights, privileges, powers and franchises of the
Company will vest in the Surviving Corporation, and all of the debts, liabilities, obligations and
duties of the Company will become the debts, liabilities, obligations and duties of the Surviving
Corporation.
Section 2.2 Closing; Effective Time.
(a) The closing of the Merger (the “Closing”) shall take place at the offices of
Xxxxxx, Xxxx & Xxxxxxxx LLP, 000 Xxxxx Xxxxx Xxxxxx, Xxx Xxxxxxx, Xxxxxxxxxx 00000, at 10:00 A.M.,
Pacific time, on the second Business Day following the satisfaction or, to the extent permitted by
applicable Law, waiver of all conditions to the obligations of the parties set forth in Article VII
(other than such conditions as may, by their terms, only be satisfied by action taken at the
Closing or on the Closing Date, but subject to the satisfaction or waiver of those conditions), or
at such other place or at such other time or on such
other date as the parties mutually may agree in writing. The day on which the Closing takes
place is referred to as the “Closing Date.”
(b) As soon as practicable on the Closing Date, the parties shall cause a certificate of
merger substantially in the form attached hereto as Exhibit A to be executed and filed with
the Secretary of State of the State of Delaware (the “Certificate of Merger”) in accordance
with the relevant provisions of Delaware Law. The Merger shall become effective upon the filing of
the Certificate of Merger with the Secretary of State of the State of Delaware or at such other
time as the parties shall agree and as shall be specified in the Certificate of Merger. The date
and time when the Merger shall become effective is herein referred to as the “Effective
Time.”
Section 2.3 Effects of the Merger. The Merger shall have the effects provided for herein and in the applicable provisions of
Delaware Law.
Section 2.4 Certificate of Incorporation and Bylaws. From and after the Effective Time, (a) the certificate of incorporation of the Surviving
Corporation shall be amended to read the same as the certificate of incorporation of Merger Sub, as
in effect immediately prior to the Effective Time until amended in accordance with the provisions
thereof and applicable Law and (b) the bylaws of the Surviving Corporation shall be amended to read
the same as the bylaws of Merger Sub, as in effect immediately prior to the Effective Time until
amended in accordance with the provisions thereof and applicable Law, in each case revised to take
into account the requirements of Section 5.12.
10
Section 2.5 Directors; Officers. From and after the Effective Time, (a) the directors of Merger Sub serving immediately
prior to the Effective Time shall be the directors of the Surviving Corporation until the earlier
of their resignation or removal or until their respective successors are duly elected and
qualified, as the case may be, and (b) the individuals set forth on Exhibit B shall serve
as officers of the Company in the capacities set forth opposite such individuals’ named until the
earlier of their resignation or removal or until their respective successors are duly elected and
qualified, as the case may be.
Section 2.6 Subsequent Actions. If, at any time after the Effective Time, the Surviving Corporation shall consider or be
advised that any deeds, bills of sale, assignments, assurances or any other actions or things are
necessary or desirable to vest, perfect or confirm of record or otherwise in the Surviving
Corporation its right, title or interest in, to or under any of the rights, properties or assets of
either the Company or Merger Sub acquired or to be acquired by the Surviving Corporation as a
result of or in connection with the Merger or otherwise to carry out this Agreement, the officers
and directors of the Surviving Corporation shall be authorized to execute and deliver, in the name
of and on behalf of either the Company or Merger Sub, all such deeds, bills of sale, assignments
and assurances and to take and do, in the name and on behalf of each of such corporations or
otherwise, all such other actions and things as may be necessary or desirable to vest, perfect
or confirm any and all right, title and interest in, to and under such rights, properties or assets
in the Surviving Corporation or otherwise to carry out the intent of this Agreement.
Section 2.7 Conversion of Stock. At the Effective Time, by virtue of the Merger and without any further action on the part
of the Acquiror, Merger Sub, the Company or any holder of any shares of Company Common Stock (the
“Common Shares”), any shares of the Company Preferred Stock (the “Preferred Shares”
and, collectively with the Common Shares, the “Shares”), or any shares of capital stock of
Merger Sub:
(a) Each Common Share issued and outstanding immediately prior to the Effective Time (other
than any Common Shares described in Sections 2.7(c) or (d) and any Dissenting Shares) shall be
converted into the right to receive the Per Share Merger Consideration, in cash, without interest;
(b) Each Preferred Share issued and outstanding immediately prior to the Effective Time shall
be converted into the right to receive an amount equal to the Liquidation Preference Per Share plus
the Per Share Merger Consideration, in cash, without interest;
(c) Each Share that is owned by Acquiror or Merger Sub immediately prior to the Effective Time
shall automatically be cancelled and retired and shall cease to exist, and no cash or other
consideration shall be delivered or deliverable in exchange therefor;
(d) Each Share that is held in the treasury of the Company or owned by the Company or any of
the Company Affiliates immediately prior to the Effective Time shall automatically be cancelled and
retired and shall cease to exist, and no cash or other consideration shall be delivered or
deliverable in exchange therefor; and
11
(e) Each share of common stock, par value $0.01 per share, of Merger Sub issued and
outstanding immediately prior to the Effective Time shall be converted into one fully paid share of
common stock, par value $0.01 per share, of the Surviving Corporation.
Section 2.8 Dissenting Shares. Notwithstanding anything in this Agreement to the contrary, Shares (other than any Shares
to be cancelled pursuant to Sections 2.7(b) and 2.7(c)) outstanding immediately prior to the
Effective Time and held by a holder who has not voted in favor of the Merger or consented thereto
in writing and who has properly demanded appraisal for such Shares in accordance with XXXX §000, if
such Section provides for appraisal rights for such Shares in the Merger (“Dissenting
Shares”), shall not be converted into or be exchangeable for the right to receive the Per Share
Merger Consideration or the Liquidation Preference Per Share, as applicable, unless and until such
holder fails to perfect or withdraws or otherwise loses such holder’s right to appraisal and
payment under the DGCL. If, after the Effective Time, any such holder fails to perfect or
withdraws or loses such holder’s right to appraisal, such Dissenting Shares shall thereupon be
treated as if they had been converted as of
the Effective Time into the right to receive the Per Share Merger Consideration or the
Liquidation Preference Per Share, if any, to which such holder is entitled, without interest. The
Company shall give the Acquiror (i) prompt notice of any demands received by the Company for
appraisal of Shares, attempted written withdrawals of such demands, and any other instruments
served pursuant to the DGCL and received by the Company relating to Stockholders’ rights to
appraisal with respect to the Merger and (ii) the opportunity to direct all negotiations and
proceedings with respect to any exercise of such appraisal rights under the DGCL. The Company
shall not, except with the prior written consent of the Acquiror, voluntarily make any payment with
respect to any demands for payment of fair value for capital stock of the Company, offer to settle
or settle any such demands or approve any withdrawal of any such demands.
Section 2.9 Options. At the Effective Time, unless otherwise agreed to in writing by the Company and any
affected Option holder, each Option outstanding immediately prior to the Effective Time, whether
vested or unvested, shall be automatically converted into the right to receive an amount in cash
equal to the product of (i) the number of Shares for which such Option is exercisable multiplied by
(ii) the difference of (A) the Per Share Merger Consideration minus (B) the per share exercise
price of such Option, less any applicable withholding taxes.
Section 2.10 Payment for Shares.
(a) At least ten Business Days prior to the Effective Time, the Acquiror shall designate a
bank or trust company reasonably acceptable to the Company to act as paying agent in connection
with the Merger (the “Paying Agent”) pursuant to a paying agent agreement (the “Paying
Agent Agreement”) providing for, among other things, the matters set forth in this Section 2.10
and otherwise reasonably satisfactory to the Company. Immediately prior to the Effective Time, the
Acquiror shall deposit or shall cause to be deposited with the Paying Agent for the benefit of any
holder of Common Shares, Preferred Shares and Options, as applicable, the consideration to which
such parties shall be entitled at the Effective Time pursuant to Sections 2.7(a), 2.7(b) and 2.9.
Such funds shall be invested by the Paying Agent as provided for in the Paying Agent Agreement, as
the case may be, pending payment therefor by the Paying Agent to Stockholders. Earnings from such
investments shall be the sole and exclusive property
12
of the Acquiror, and no part thereof shall
accrue to the benefit of the holders of Common Shares, Preferred Shares or Options.
(b) At least two Business Days prior to the Closing Date, the Acquiror shall provide to each
holder of record of a certificate or certificates that, immediately prior to the Effective Time,
evidenced outstanding Shares (the “Certificates”) and whose Shares will be converted into
the right to receive the consideration described in Section 2.7(a) or Section 2.7(b), (i) a letter
of transmittal (which shall specify that delivery shall be effected, and risk of loss and title to
the Certificates shall pass, only upon proper delivery of the Certificates to the Paying Agent and
shall be in such form and have such other provisions as the Acquiror may reasonably specify) (the
“Letter of Transmittal”) and (ii) instructions for use in effecting the surrender of the
Certificates in exchange for payment therefor. Following the Effective Time, upon surrender of
a Certificate for cancellation to the Paying Agent or such other agent or agents as may be
appointed by the Acquiror, together with a Letter of Transmittal duly executed and completed in
accordance with the instructions thereto, the holder of such Certificate shall be entitled to
receive in exchange therefor (as promptly as reasonably practicable on or after the Closing Date),
(A) in the case of Certificates representing Common Shares, an amount in cash equal to (1) the Per
Share Merger Consideration multiplied by (2) the number of Common Shares formerly represented by
such Certificate and (B) in the case of Certificates representing Preferred Shares, an amount in
cash equal to (1) the Liquidation Preference Per Share multiplied by the number of Preferred Shares
represented by such Certificate (2) plus the Per Share Merger Consideration multiplied by the
number of Preferred Shares formerly represented by such Certificate, in each case without interest,
and such Certificate shall, upon such surrender, be cancelled. If any Certificate, together with a
duly executed and completed Letter of Transmittal, is delivered to the Paying Agent or such other
agent prior to the Effective Time, then the holder of such Certificate shall be entitled to receive
such payment on the Closing Date. If payment in respect of any Certificate is to be made to a
Person other than the Person in whose name such Certificate is registered, it shall be a condition
of payment that the Certificate so surrendered shall be properly endorsed or shall otherwise be in
proper form for transfer, that the signatures on such Certificate or any related stock power shall
be properly guaranteed and that the Person requesting such payment shall have established to the
satisfaction of the Acquiror and the Paying Agent that any transfer and other Taxes required by
reason of such payment to a Person other than the registered holder of such Certificate have been
paid or are not applicable. Until surrendered in accordance with the provisions of this Section
2.10 and the Letter of Transmittal, any Certificate (other than Certificates representing Shares
described in Sections 2.7(c) and (d) and any Dissenting Shares) shall be deemed, at any time after
the Effective Time, to represent only the right to receive the Per Share Merger Consideration or
the Liquidation Preference Per Share payable with respect thereto, in cash, without interest, as
contemplated herein. Notwithstanding anything in this Agreement to the contrary, on the Closing
Date, the Company shall (and Acquiror shall cause the Company) to pay up to $2,500,000 of the
Merger Consideration to employees of the Company as directed by the Company in writing at any time
prior to the date that is two Business Days prior to the Closing Date, and the Merger
Consideration, for purposes of calculating the Per Share Merger Consideration, shall be deemed to
be reduced by such amount.
(c) At the Effective Time, the stock transfer books of the Company shall be closed and there
shall be no further registration of transfers of any shares of capital stock thereafter on the
records of the Company. If, after the Effective Time, a Certificate (other
13
than representing
Shares described in Sections 2.7(c) and (d)) is presented to the Surviving Corporation, it shall be
cancelled and exchanged as provided in this Section 2.10.
(d) All cash paid upon conversion of the Shares in accordance with the terms of this Article
II shall be deemed to have been paid in full satisfaction of all rights pertaining to such Shares.
From and after the Effective Time, the holders of Certificates shall cease to have any rights with
respect to Shares represented thereby, except as otherwise provided herein or by applicable Law.
(e) If any Certificate shall have been lost, stolen or destroyed, upon the making of an
affidavit of that fact by the holder thereof, the Surviving Corporation shall pay or cause to be
paid in exchange for such lost, stolen or destroyed Certificate the Per Share Merger
Consideration or the Liquidation Preference Per Share, as applicable, payable in respect
thereof pursuant to Section 2.10(b) for Shares represented thereby; provided,
however, that the Surviving Corporation or the Paying Agent may, in their discretion,
require the delivery of a reasonably satisfactory bond or indemnity.
(f) Notwithstanding anything to the contrary in this Section 2.10, to the fullest extent
permitted by law, none of the Paying Agent, the Acquiror or the Surviving Corporation shall be
liable to any holder of a Certificate for any amount properly delivered to a public official
pursuant to any applicable abandoned property, escheat or similar law.
Section 2.11 Withholding Rights. Each of the Acquiror, the Surviving Corporation and the Paying Agent shall be entitled to
deduct and withhold from any consideration otherwise payable to any Person pursuant to this
Agreement such amounts as it is required or reasonably believes it is required to deduct and
withhold with respect to the making of such payment under the Code, or any provision of applicable
tax Law. To the extent that such amounts are so withheld or paid over to or deposited with the
relevant Governmental Authority by the Acquiror, the Surviving Corporation or the Paying Agent,
such withheld amounts shall be treated for all purposes of this Agreement as having been paid to
the applicable Person in respect to which such deduction and withholding was made.
ARTICLE III
REPRESENTATIONS AND WARRANTIES
OF THE COMPANY
REPRESENTATIONS AND WARRANTIES
OF THE COMPANY
Except as set forth in the letter (the “Disclosure Letter”) delivered by the Company
to the Acquiror and Merger Sub concurrently with the execution of this Agreement (it being agreed
that disclosure of any item in any section of the Disclosure Letter shall be deemed disclosure with
respect to any other section of the Disclosure Letter to which the relevance of such item is
reasonably apparent), the Company hereby represents and warrants to the Acquiror and Merger Sub as
follows:
Section 3.1 Organization and Qualification.
(a) Each of the Company and the Company Affiliates is (i) duly organized, validly existing and
in good standing under the laws of the jurisdiction of its formation as set forth in Section 3.1(a)
of the Disclosure Letter, and has full power and authority to own, lease
14
and operate its properties
and to carry on its business as it is now being conducted and (ii) duly qualified or licensed as a
foreign corporation to do business, and is in good standing, in each jurisdiction where the
character of the properties owned, leased or operated by it or the nature of its business makes
such qualification or licensing necessary, except for any such failures to be so qualified or
licensed and in good standing that, individually or in the aggregate, have not had and would not
reasonably be expected to have a Material Adverse Effect.
(b) The Company has heretofore furnished to the Acquiror a complete and correct copy of the
certificate of incorporation and bylaws or equivalent organizational documents, each as amended to
date, of the Company and each of the Company Affiliates. Such certificates of incorporation,
bylaws or equivalent organizational documents are in full force and effect. Neither the Company
nor any of the Company Affiliates is in violation of any of the provisions of its certificate of
incorporation, bylaws or equivalent organizational documents. The transfer books and minute books
of each of the Company and the Company Affiliates that have been made available for inspection by
the Acquiror prior to the date hereof are true and complete in all material respects.
Section 3.2 Authority.
(a) The Company has full corporate power and authority to execute and deliver this Agreement
and to perform its obligations hereunder and to consummate the transactions contemplated hereby.
The execution, delivery and performance by the Company of this Agreement and the consummation by
the Company of the transactions contemplated hereby have been duly and validly authorized by the
Board of Directors of the Company. Other than the Company Stockholder Approval, no other corporate
proceedings on the part of the Company, the Stockholders, or the holders of Preferred Shares are
necessary to authorize the execution, delivery or performance of this Agreement by the Company or
for the Company to consummate the transactions contemplated hereby. This Agreement has been duly
executed and delivered by the Company. This Agreement constitutes the legal, valid and binding
obligations of the Company, enforceable against the Company in accordance with its terms.
(b) The Board of Directors of the Company, at a meeting thereof duly called and held on
October 10, 2007, (i) determined that this Agreement and the Merger are fair to and in the best
interests of the Company and its stockholders and (ii) resolved to recommend that the Stockholders
approve and adopt this Agreement and the Merger.
(c) The Company Stockholder Approval constitutes the only approval of the Stockholders
necessary for the Company to consummate the transactions contemplated by this Agreement under the
Company’s certificate of incorporation and bylaws and the DGCL.
Section 3.3 No Conflict; Required Filings and Consents.
(a) Assuming the receipt of the Company Stockholder Approval and the making or receipt of the
notices, authorizations, approvals, orders, permits and consents described in clause (b) below, the
execution, delivery and performance by the Company of this Agreement and the consummation of the
transactions contemplated hereby do not and will not:
15
(i) conflict with or violate the certificate of incorporation or bylaws or equivalent
organizational documents of the Company or any of the Company Affiliates;
(ii) conflict with or violate any Law applicable to the Company or any of the Company
Affiliates or by which any property or asset of the Company or any of the Company Affiliates
is bound or affected; or
(iii) result in any breach of, constitute a default (or an event that, with notice or
lapse of time or both, would become a default) under, require any consent of any Person
pursuant to, give to others any right of termination, amendment, modification, acceleration
or cancellation of, allow the imposition of any fees or penalties, require the offering or
making of any payment or redemption, give rise to any increased, guaranteed, accelerated or
additional rights or entitlements of any Person or otherwise adversely affect any rights of
the Company or any of the Company Affiliates under, or result in the creation of any
Encumbrance on any property, asset or right of the Company or any of the Company Affiliates
pursuant to, any note, bond, mortgage, indenture, agreement, lease, license, permit,
franchise, instrument, obligation or other Contract to which the Company or any of the
Company Affiliates is a party or by which the Company or any of the Company Affiliates or
any of their respective properties, assets or rights are bound or affected;
except, in the cases of clauses (ii) and (iii), for such conflicts, violations, breaches, defaults
or other occurrences that, individually or in the aggregate, have not had and would not reasonably
be expected to have a Material Adverse Effect.
(b) Neither the Company nor any of the Company Affiliates is required to file, seek or obtain
any material notice, authorization, approval, order, permit or consent of or with any Governmental
Authority in connection with the execution, delivery and performance by the Company of this
Agreement or the consummation of the transactions contemplated hereby or in order to prevent the
termination of any right, privilege, license or qualification of the Company or any of the Company
Affiliates, other than (i) the filing and recordation of the Certificate of Merger with the
Secretary of State of the State of Delaware and such filings with Governmental Authorities to
satisfy the applicable Laws of states in which the Company and the Company Affiliates are qualified
to do business, (ii) such filings and approvals as may be required by any federal or state
securities Laws, including compliance with any applicable requirements of the Exchange Act, and
(iii) compliance with any applicable requirements of the Xxxx-Xxxxx-Xxxxxx Antitrust Improvements
Act of 1976, as amended (the “HSR Act”), and any other applicable foreign Laws, antitrust,
competition or merger control Laws of any jurisdiction.
(c) No “fair price,” “interested shareholder,” “business combination” or similar provision of
any state takeover Law is, or at the Effective Time will be, applicable to the transactions
contemplated by this Agreement.
Section 3.4 Capitalization.
(a) The authorized capital stock of the Company consists of (i) 10,000,000 shares of Company
Common Stock,
16
of which 10,000 shares of Company Common Stock, constituting the Common Shares, are issued and outstanding on the date hereof, and (ii)
1,000,000 shares of preferred stock, of which 9,642 shares of Company Preferred Stock, constituting
the Preferred Shares, are issued and outstanding on the date hereof. There are 3,825 options to
purchase shares of Company Common Stock, constituting the Options, issued and outstanding on the
date hereof. As of the Effective Time, there shall be no Options, warrants, or other securities
convertible into or exercisable for any securities of the Company outstanding other than the
Options which will be converted into the right to receive cash pursuant to Section 2.9.
(b) Section 3.4 of the Disclosure Letter sets forth, for each Company Affiliate, the amount of
its authorized capital stock, the amount of its outstanding capital stock and the record and
beneficial owners of its outstanding capital stock. Except for the Shares and the Options, neither
the Company nor any of the Company Affiliates has issued or agreed to issue any: (i) share of
capital stock or other equity or ownership interest; (ii) option, warrant or interest convertible
into or exchangeable or exercisable for the purchase of shares of capital stock or other equity or
ownership interests; (iii) stock appreciation right, phantom stock, interest in the ownership or
earnings of the Company or any of the Company Affiliates or other equity equivalent or equity-based
award or right; or (iv) bond, debenture or other indebtedness having the right to vote or
convertible or exchangeable for securities having the right to vote. Each outstanding share of
capital stock or other equity or ownership interest of the Company and each of the Company
Affiliates is duly authorized, validly issued, fully paid and non-assessable and, in the case of
the Company Affiliates, each such share or other equity or ownership interest is owned by the
Company or another Subsidiary of the Company, free and clear of any Encumbrance. All of the
aforesaid shares or other equity or ownership interests have been offered, sold and delivered by
the Company or the Company Affiliates in material compliance with all applicable federal and state
securities laws.
(c) Except for rights granted to the Acquiror and Merger Sub under this Agreement, there are
no outstanding obligations of the Company or any of the Company Affiliates to issue, sell or
transfer or repurchase, redeem or otherwise acquire, or that relate to the holding, voting or
disposition of, or that restrict the transfer of, the issued or unissued capital stock or other
equity or ownership interests of the Company or any of the Company Affiliates. No shares of
capital stock or other equity or ownership interests of the Company or any of the Company
Affiliates have been issued in violation of any rights, agreements, arrangements or commitments
under any provision of applicable Law, the certificate of incorporation or bylaws or equivalent
organizational documents of the Company or any of the Company Affiliates or any Contract to which
the Company or any of the Company Affiliates is a party or by which the Company or any of the
Company Affiliates is bound.
Section 3.5 Equity Interests. Neither the Company nor any of the Company Affiliates directly or indirectly owns any
equity, partnership, membership or similar interest in, or any interest convertible into,
exercisable for the purchase of or exchangeable for any such equity, partnership, membership or
similar interest, or is under any current or prospective obligation to form or participate in,
provide funds to, make any loan, capital contribution or other investment in, or assume any
liability or obligation of, any Person.
17
Section 3.6 Financial Statements; No Undisclosed Liabilities.
(a) True and complete copies of the audited consolidated balance sheet of the Company and the
Company Affiliates as at December 31, 2004, 2005, 2006, and the related audited consolidated
statements of income, retained earnings, stockholders’ equity and statements of cash flows of the
Company and the Company Affiliates, together with all related notes and schedules thereto,
accompanied by the reports thereon of the Company’s independent auditors (collectively referred to
as the “Financial Statements”) and the unaudited consolidated balance sheet of the Company
and the Company Affiliates as at August 31, 2007 (the “Balance Sheet Date”), and the
related consolidated statements of income, retained earnings, stockholders’ equity and changes in
financial position of the Company and the Company Affiliates, together with all related notes and
schedules thereto (collectively referred to as the “Interim Financial Statements”) are
attached hereto as Section 3.6(a) of the Disclosure Letter. Each of the Financial Statements and
the Interim Financial Statements (i) have been prepared in accordance with GAAP applied on a
consistent basis throughout the periods indicated (except as may be indicated in the notes
thereto); and (ii) fairly present, in all material respects, the consolidated financial position,
results of operations and cash flows of the Company and the Company Affiliates as at the respective
dates thereof and for the respective periods indicated therein, except as otherwise noted therein
and subject, in the case of the Interim Financial Statements, to normal and recurring year-end
adjustments that would not reasonably be expected to be, individually or in the aggregate,
material.
(b) Except as and to the extent reflected in the Financial Statements or the Interim Financial
Statements, neither the Company nor any of the Company Affiliates has any liability or obligation
of any nature, whether accrued, absolute, contingent or otherwise, whether known or unknown, (i)
that is required by GAAP to be reflected in a consolidated balance sheet of the Company and the
Company Affiliates or disclosed in the notes thereto, except for liabilities and obligations, (1)
incurred after the Balance Sheet Date in the ordinary course of business consistent with past
practice, (2) that, individually or in the aggregate, have not and would not reasonably be expected
to have a Material Adverse Effect or (3) expressly permitted or required by this Agreement, or (ii)
arising out of or related to Coram Healthcare Corporation.
(c) The records, systems, controls, data and information of the Company is recorded, stored,
maintained and operated under means (including any electronic, mechanical, scanning/imaging, or
photographic process, whether computerized or not) that are under the exclusive ownership and
direct control of the Company (including all means of access thereto and therefrom), except for any
non-exclusive ownership and non-direct control that would not have a materially adverse effect on
the system of internal accounting controls described in the following sentence. The Company has
devised and maintain a system of internal accounting controls sufficient to provide reasonable
assurances regarding the reliability of financial reporting and the timely preparation and
reliability of financial statements in accordance with GAAP. The Company has designed controls and
procedures to ensure that material information relating to the Company is made known to the
management of the Company by others within the Company.
(d) There are no significant deficiencies, including material weaknesses, in the design or
operation of the Company’s internal controls that materially adversely affect the
18
Company’s ability
to record, process, summarize, and report financial data. To the knowledge of the Company, the
officers of the Company have identified for the Company’s auditors any material weaknesses in
internal controls and any fraud, whether or not material, that involves management or other
employees of the Company who have a significant role in the Company’s internal controls. The
Company has made available to Acquiror a summary of any such disclosures that have been made by
management to the Company’s auditors since January 1, 2004.
Section 3.7 Accounts Receivable. As of the date hereof, the Accounts Receivable of the Company and the Company Affiliates
reflected in their respective books and records represent in all material respects valid and
enforceable obligations arising from bona fide transactions in the ordinary course of business.
Section 3.8 Customers and Suppliers.
(a) Section 3.8(a) of the Disclosure Letter sets forth a true and complete list of the top 25
payors of the Company and the Company Affiliates (determined on the basis of revenues) for the
twelve month period ending June 30, 2007. As of the date hereof, (i) neither the Company nor any
of the Company Affiliates has received any written notice, and the Company has no knowledge, that
any of such payors (A) has ceased or substantially reduced, or will cease or substantially reduce,
use of products or services of the Company or the Company Affiliates or (B) has sought, or is
seeking, to reduce the price it will pay for the services of the Company or the Company Affiliates
and (ii) none of such payors has, to the knowledge of the Company, otherwise threatened to take any
action described in the preceding sentence as a result of the consummation of the transactions
contemplated by this Agreement.
(b) Section 3.8(b) of the Disclosure Letter sets forth a true and complete list of the top 52
suppliers of the Company and the Company Affiliates (determined on the basis of payables to such
suppliers) for the twelve month period ending June 30, 2007. As of the date hereof, (i) neither
the Company nor any of the Company Affiliates has received any notice, and the Company has no
knowledge, that (A) there has been any material adverse change in the price of such supplies or
services provided by any such supplier, or (B) any such supplier will not sell supplies or services
to the Surviving Corporation and the Company Affiliates at any time after the Closing Date on terms
and conditions substantial the same or better than those used in its current sales to the Company
and the Company Affiliates and (ii) no such supplier has, to the knowledge of the Company,
otherwise threatened to take any action described in the preceding sentence as a result of the
consummation of the transactions contemplated by this Agreement.
Section 3.9 Absence of Certain Changes or Events. From the Balance Sheet Date through the date of this Agreement: (a) the Company and the
Company Affiliates have conducted their businesses only in the ordinary course consistent
with past practice; (b) there has not been any event, change, circumstance, effect or state of
facts that, individually or in the aggregate, has had or is reasonably likely to have a Material
Adverse Effect; (c) neither the Company nor any of the Company Affiliates has suffered any material
damage, destruction or other material casualty affecting any of its material real and personal
properties or assets, whether or not covered by insurance; (d) the Company has not declared, set
aside, or made or paid any dividend or other distribution, payable in cash, stock, property or
otherwise, or made
19
any other payment on or with respect to any of its capital stock, except for
dividends by any direct or indirect wholly owned Subsidiary of the Company; and (e) none of the
Company or any of the Company Affiliates has taken any action that, if taken after the date of this
Agreement, would constitute a breach of any of the covenants set forth in Sections 5.1(a) through
(h) and (j) through (t).
Section 3.10 Compliance with Law; Permits.
(a) Since January 1, 2005, (i) each of the Company and the Company Affiliates is and has been
in compliance with all Laws applicable to it and (ii) none of the Company, any of the Company
Affiliates or any of its or their executive officers has received any notice, order, complaint or
other communication from any Governmental Authority or any other Person that the Company or any of
the Company Affiliates is not in compliance with any Law applicable to it, except where such
non-compliance, individually or in the aggregate, has not had and would not reasonably be expected
to have a Material Adverse Effect.
(b) Section 3.10(b) of the Disclosure Letter sets forth a true and complete list of all
permits, licenses, franchises, approvals, certificates, consents, waivers, concessions, exemptions,
orders, registrations, notices or other authorizations of any Governmental Authority necessary for
it to own, lease and operate its properties and to carry on its business as currently conducted
(the “Permits”), except where the failure to have such Permits, individually or in the
aggregate, has not had and would not reasonably be expected to have a Material Adverse Effect.
Each of the Company and the Company Affiliates is and has been in compliance in all material
respects with all such Permits. No suspension, cancellation, modification, revocation or
non-renewal of any Permit is pending or, to the knowledge of the Company, threatened. The Company
and the Company Affiliates will continue to have the use and benefit of all Permits following
consummation of the transactions contemplated hereby, except where the failure to have such
Permits, individually or in the aggregate, has not had and would not reasonably be expected to have
a Material Adverse Effect. No Permit is held in the name of any employee, officer, director,
stockholder, agent or otherwise on behalf of the Company or any of the Company Affiliates.
Section 3.11 Litigation. As of the date hereof, there is no Action (except for any Actions commenced by Persons
other than Governmental Authorities that would not reasonably be expected to result in a liability
or loss to the Company or the Company Affiliates of more than $150,000 individually or more than
$500,000 in the aggregate) pending or, to the knowledge of the Company, threatened against the
Company or any of the Company Affiliates, or any material property or asset of the
Company or any of the Company Affiliates. Since the date hereof through the Closing Date,
there is no Action pending or, to the knowledge of the Company, threatened against the Company or
any of the Company Affiliates, or any material property or asset of the Company or any of the
Company Affiliates, except as would not reasonably be expected to have, individually or in the
aggregate, a Material Adverse Effect. As of the date of this Agreement, (i) there is no Action
pending or, to the knowledge of the Company, threatened seeking to prevent, hinder, modify, delay
or challenge the transactions contemplated by this Agreement and (ii) there is no outstanding
order, writ, judgment, injunction, decree, determination or award of, or pending or, to the
knowledge of the Company, threatened investigation by, any Governmental Authority relating to the
Company, any of the Company
20
Affiliates, any of their respective properties or assets that, in the
case of clause (ii), is (A) material to the business of the Company or (B) arises out of any
material violation of any applicable Healthcare Law. As of the date of this Agreement, there are
no material Actions by the Company or any of the Company Affiliates pending, or which the Company
or any of the Company Affiliates has commenced preparations to initiate, against any other Person.
Section 3.12 Employee Benefit Plans.
(a) Section 3.12(a) of the Disclosure Letter sets forth a true and complete list of all
employee benefit plans (as defined in Section 3(3) of the Employee Retirement Income Security Act
of 1974, as amended (“ERISA”)) and all bonus, stock option, stock purchase, restricted
stock, incentive, deferred compensation, retiree medical or life insurance, supplemental
retirement, severance, termination pay, salary continuation, employment, consulting,
indemnification, layoff, unemployment, change in control or other benefit plans, programs,
policies, practices, arrangements or Contracts, to which the Company or any of its Subsidiaries is
a party, with respect to which the Company or any of its Subsidiaries has any liability or
obligation or which are maintained, contributed to or sponsored by the Company or any of its
Subsidiaries for the benefit of any current or former employee, consultant, officer or director of
the Company or any of its Subsidiaries (the “Plans”).
(b) The Company has furnished to the Acquiror a true and complete copy of each Plan (or, with
respect to each unwritten Plan, a written summary thereof) and has delivered to the Acquiror a true
and complete copy of each material document, if any, prepared in connection with each such Plan,
including (i) a copy of each trust or other funding arrangement, (ii) each summary plan description
and summary of material modifications, (iii) the two most recently filed Internal Revenue Service
(“IRS”) Form 5500, (iv) the most recently received IRS determination letter for each such
Plan and (v) the two most recently prepared actuarial report and financial statement in connection
with each such Plan. Neither the Company nor any of its Subsidiaries has any express or implied
commitment (A) to create, incur liability with respect to or cause to exist any employee benefit
plan, program, policy, practice or arrangement (other than the Plans set forth on Section 3.12(a)
of the Disclosure Letter), (B) to enter into any Contract to provide compensation or benefits to
any individual or (C) to modify, change or terminate any Plan, other than with respect to a
modification, change or termination
required by ERISA or the Internal Revenue Code of 1986, as amended (the “Code”).
(c) None of the Plans is (i) subject to Title IV of ERISA, (ii) a multiemployer plan within
the meaning of Section 3(37) or 4001(a)(3) of ERISA (a “Multiemployer Plan”) or (iii) a
single employer pension plan within the meaning of Section 4001(a)(15) of ERISA for which the
Company or any of the Company Affiliates could incur liability under Section 4063 or 4064 of ERISA
(a “Multiple Employer Plan”). Neither the Company nor any ERISA Affiliate has ever during
the past six years maintained, sponsored, contributed to, or incurred any liability or obligation
with respect to any employee benefit plan subject to Title IV of ERISA or Section 412 of the Code.
None of the Plans: (i) provides for the payment of separation, severance, termination or
similar-type benefits to any person; (ii) obligates the Company or its Subsidiaries to pay
separation, severance, termination or similar-type benefits solely or partially as a result of the
transactions
21
contemplated by this Agreement; or (iii) obligates the Company or any of its
Subsidiaries to make any payment or provide any benefit as a result of the transactions
contemplated by this Agreement. None of such Plans provides for or promises retiree medical,
disability or life insurance benefits to any current or former employee, officer or director of the
Company or any of the Company Affiliates. Each of the Plans is maintained in the United States.
(d) Each Plan is now and always has been operated in all material respects in accordance with
its terms and the requirements of all applicable Laws, including ERISA and the Code. Each of the
Company and the Company Affiliates has performed all material obligations required to be performed
by it and is not in any respect in default under or in violation under any Plan, nor does the
Company have any knowledge of any such default or violation by any other party to any Plan. No
material Action is pending or, to the knowledge of the Company, threatened with respect to any
Plan, other than claims for benefits in the ordinary course, and, to the knowledge of the Company,
no fact or event exists that would give rise to any such Action.
(e) Each Plan that is intended to be qualified under Section 401(a) of the Code or Section
401(k) of the Code has received a timely favorable determination or opinion letter from the IRS
covering all of the provisions applicable to the Plan for which determination or opinion letters
are currently available that the Plan is so qualified. To the knowledge of the Company, no fact or
event has occurred since the date of such determination or opinion letter or letters from the IRS
that could adversely affect the qualified status of any such Plan.
(f) There has not been any non-exempt prohibited transaction, within the meaning of Section
406 of ERISA or Section 4975 of the Code, with respect to any Plan that would result in any
material liability to the Company or its Subsidiaries. Neither the Company nor any of the Company
Affiliates has incurred any material liability under, arising out of or by operation of Title IV of
ERISA, other than liability for premiums to the Pension Benefit Guaranty Corporation arising in the
ordinary course, including any liability in connection with (i) the termination or reorganization
of any employee benefit plan subject to Title IV of ERISA or (ii) the withdrawal from any
Multiemployer Plan or Multiple Employer Plan, and no fact or event exists that would give rise to
any such liability. There does not exist any Controlled Group
Liability that would reasonably be expected to be a liability (contingent or otherwise) of the
Company or any of its Subsidiaries following the Closing.
(g) All material contributions, premiums or payments required to be made with respect to any
Plan have been made on or before their due dates. There are no suits, actions, disputes, claims
(other than routine claims for benefits), arbitrations, administrative or other proceedings pending
or, to the knowledge of the Company, threatened, anticipated or expected to be asserted with
respect to any Plan or any related trust or other funding medium thereunder or with respect to the
Company or any Subsidiary as the sponsor or fiduciary thereof or with respect to any other
fiduciary thereof that would result in any material liability to the Company or its Subsidiaries.
In accordance with applicable law, each Plan (other than any Plan that is an employment, severance,
change of control or similar agreement) can be amended or terminated by the Company at any time,
without consent from any other person and without material liability other than for benefits
accrued as of the date of such amendment or termination (other than administrative expenses
incurred as a result of such termination) or liabilities that arise under applicable Law.
22
(h) Neither the execution and delivery of this Agreement nor the consummation of the
transactions contemplated hereby (either alone or in combination with any other event) will (i)
result in any payment (including severance, golden parachute, bonus or otherwise), becoming due to
any current or former employee, consultant, officer or director of the Company or any of the
Company Affiliates, (ii) result in any forgiveness of indebtedness to any current or former
employee, consultant, officer or director of the Company or any of the Company Affiliates, (iii)
increase any benefits otherwise payable by the Company under any Plan or (iv) result in the
acceleration of the time of payment or vesting of any such benefits, except as required under
Section 411(d)(3) of the Code. There is no agreement, plan, arrangement or other Contract by which
the Company is bound to compensate any individual for excise taxes paid pursuant to Section 4999 of
the Code.
(i) Each Plan that is a nonqualified deferred compensation plan (as defined under Section 409A
of the Code) satisfies the applicable requirements of Sections 409A(a)(2),(3), and (4) of the Code,
and has, since January 1, 2005, been operated in good faith compliance with Sections 409A(a)(2),
(3), and (4) of the Code. Each Option, stock appreciation right other similar right to acquire
Company Common Stock has an exercise price that has never been and may never be less than the fair
market value of the underlying equity as of the date such Option, stock appreciation right or other
similar right was granted in accordance with all governing documents and in compliance with all
applicable law.
Section 3.13 Labor and Employment Matters.
(a) Since January 1, 2004, neither the Company nor any of the Company Affiliates is a party to
any labor or collective bargaining Contract that pertains to employees of the Company or any of the
Company Affiliates. There are no organizing activities or collective bargaining arrangements that
would affect the Company or any of the Company Affiliates pending or under discussion with any
labor organization or group of employees of the Company
or any of the Company Affiliates. There is, and during the past five years there has been, no
material labor dispute, strike, controversy, slowdown, work stoppage or lockout pending or, to the
knowledge of the Company, threatened against or affecting the Company or any of the Company
Affiliates. There are no pending or, to the knowledge of the Company, threatened union grievances
or union representation questions involving employees of the Company or any of the Company
Affiliates.
(b) All employees working in the United States hired by the Company or any of the Company
Affiliates on or after November 7, 1986 are authorized for employment by the Company or such
Company Affiliate in the United States in accordance with the Immigration and Naturalization Act,
as amended, and the regulations promulgated thereunder. No allegations of immigration-related
unfair employment practices have been made with the Equal Employment Opportunity Commission or the
Special Counsel for Immigration-Related Unfair Employment Practices. Each of the Company and the
Company Affiliates has completed and retained in accordance with the Immigration and Naturalization
Service regulations a Form I-9 for all employees working in the United States hired on or after
November 7, 1986, except those employees whose employment terminated on or before June 1, 1987.
None of the employees currently employed by the Company or any of the Company Affiliates is
authorized for
23
employment in the United States pursuant to a nonimmigrant visa that authorizes the
employee to be employed by the Company or any of the Company Affiliates.
(c) Neither the Company nor any of the Company Affiliates has engaged or is engaging in any
unfair labor practice. No unfair labor practice or labor charge or complaint is pending or, to the
knowledge of the Company, threatened with respect to the Company or any of the Company Affiliates
before the National Labor Relations Board, the Equal Employment Opportunity Commission or any other
Governmental Authority.
(d) The Company and each of the Company Affiliates have withheld and paid to the appropriate
Governmental Authority or are holding for payment not yet due to such Governmental Authority all
amounts required to be withheld from employees of the Company or any of the Company Affiliates and
are not liable for any arrears of wages, taxes, penalties or other sums for failure to comply with
any applicable Laws relating to the employment of labor. The Company and each of the Company
Affiliates have paid in full to all their respective employees or adequately accrued in accordance
with GAAP for all wages, salaries, commissions, bonuses, benefits and other compensation due to or
on behalf of such employees.
(e) Neither the Company nor any of the Company Affiliates is a party to, or otherwise bound
by, any consent decree with, or citation by, any Governmental Authority relating to employees or
employment practices. None of the Company, any of the Company Affiliates or any of its or their
executive officers has received within the past five years any notice of intent by any Governmental
Authority responsible for the enforcement of labor or employment laws to conduct an investigation
relating to the Company or any of the Company Affiliates and, to the knowledge of the Company, no
such investigation is in progress. All individuals who are performing consulting or other services
for a Company or any of the Company Affiliates are or were correctly classified as either
“independent contractors” or “employees,” as the case may be, and, at the Closing Date, will
qualify for such classification with immaterial exceptions.
(f) As of the date of this Agreement, none of the employees set forth on Section 3.13(f) of
the Disclosure Letter has informed Xxxx X. Xxxxxxx, nor does Xxxx X. Xxxxxxx have actual knowledge
that such employee intends to terminate his or her employment relationship with the Company prior
to, concurrently with or within the first six months following the consummation of the transactions
contemplated hereby.
Section 3.14 Assets.
(a) The Company or the Company Affiliates have good and valid title to, or a valid leasehold
interest in or other valid legal right to use, all of the assets used by the Company and the
Company Affiliates to carry on their respective businesses as currently conducted. Except as
reflected or reserved against on the Balance Sheet or incurred after the Balance Sheet Date in the
ordinary course of business, none of the assets owned or leased by the Company or any of the
Company Affiliates is subject to any Encumbrance, other than Permitted Encumbrances.
24
(b) This Section 3.14 does not relate to real property or interests in real property, such
items being the subject of Section 3.15, or to Intellectual Property, such items being the subject
of Section 3.16.
Section 3.15 Real Property.
(a) Section 3.15(a) of the Disclosure Letter sets forth a true and complete list of all Owned
Real Property and all Leased Real Property. Each of the Company and the Company Affiliates has (i)
good and marketable title in fee simple to all Owned Real Property and (ii) good and marketable
leasehold title to all Leased Real Property, in each case, free and clear of all Encumbrances
except Permitted Encumbrances. No parcel of Owned Real Property or Leased Real Property is subject
to any governmental decree or order to be sold or is being condemned, expropriated or otherwise
taken by any public authority with or without payment of compensation therefore, nor, to the
knowledge of the Company, has any such condemnation, expropriation or taking been proposed. All
leases of Leased Real Property and all amendments and modifications thereto are in full force and
effect, and there exists no default under any such lease by the Company, any of the Company
Affiliates or any other party thereto, nor any event which, with notice or lapse of time or both,
would constitute a default thereunder by the Company, any of the Company Affiliates or any other
party thereto. All leases of Leased Real Property shall remain valid and binding in accordance
with their terms following the Closing, except where the failure to remain valid and binding,
individually or in the aggregate, has not had and would not reasonably be expected to have a
Material Adverse Effect.
(b) There are no contractual or legal restrictions that preclude or restrict the ability to
use any Owned Real Property or Leased Real Property by the Company or any of the Company Affiliates
for the current or contemplated use of such real property. There are no material latent defects or
material adverse physical conditions affecting the Owned Real Property or Leased Real Property.
All plants, warehouses, distribution centers, structures and other
buildings on the Owned Real Property or Leased Real Property are adequately maintained and are
in good operating condition and repair for the requirements of the business of the Company and the
Company Affiliates as currently conducted.
Section 3.16 Intellectual Property.
(a) All Intellectual Property that the Company or any of the Company Affiliates are using in
the conduct of their respective businesses as currently conducted is solely owned by the Company or
such Company Affiliate or has been licensed to the Company or such Company Affiliate by a third
party under a valid and enforceable written agreement. The execution, delivery and performance by
the Company and, as applicable, the Company Affiliates of this Agreement will not result in the
loss or impairment of, or give rise to any right of a third party to terminate, any rights of the
Company or any Company Affiliate in any such Intellectual Property, except as, individually or in
the aggregate, has not had and would not reasonably be expected to have a Material Adverse Effect.
(b) (i) To the knowledge of the Company neither the Company and nor the Company Affiliates
have infringed upon, misappropriated, diluted or otherwise violated any Intellectual Property of
any third party and (ii) there is no pending or, to the knowledge of the
25
Company, threatened claim
in writing against the Company or any of the Company Affiliates claiming that the Company or any of
the Company Affiliates has infringed, misappropriated, diluted or otherwise violated any
Intellectual Property right of any other Person.
(c) To the knowledge of the Company, no Person has infringed, misappropriated, diluted or
otherwise violated any Intellectual Property owned by the Company or any of the Company Affiliates.
Section 3.16(c) of the Disclosure Letter sets forth, as of the date hereof, a list of all issued
patents, pending patent applications, registered copyrights and pending applications for
registration of copyrights, registered trademarks and applications and registered domain names
owned by the Company or any of the Company Affiliates. Except as, individually or in the
aggregate, has not had and would not reasonably be expected to have a Material Adverse Effect, all
such Intellectual Property is valid and enforceable; no claim is pending challenging the validity,
enforceability, registration, ownership or use of such Intellectual Property; and the Company or
the Company Affiliate, as applicable, is the sole and exclusive owner of the entire right, title,
and interest in and to all such Intellectual Property free and clear of any Encumbrances (other
than Permitted Encumbrances).
(d) All Intellectual Property owned by the Company that derives independent economic value
from not being generally known to the public has been maintained in confidence in accordance with
protection procedures consistent with industry standards.
(e) No Intellectual Property owned by or licensed to the Company or any of the Company
Affiliates is subject to any outstanding order, judgment, decree, stipulation or agreement
restricting the use or licensing thereof by the Company or the Company Affiliates.
Section 3.17 Taxes.
(a) Each of the Company and the Company Affiliates has timely filed all material Returns
required to be filed by it. All Returns filed by the Company and the Company Affiliates are
accurate, complete, and correct in all material respects and no such Return contains, or was
required to contain (in order to avoid a material penalty) a disclosure statement under Section
6662 of the Code or any predecessor provision or comparable provision of state, local or foreign
Law. Each of the Company and the Company Affiliates is and has been in compliance in all material
respects with all applicable Laws pertaining to Taxes, including all applicable Laws relating to
record retention and in all material respects with all rules and regulations relating to the
withholding of Taxes.
(b) Each of the Company and the Company Affiliates has timely paid all material Taxes that
have become due or payable (whether or not shown on a Return) and has adequately provided for in
the Financial Statements and Interim Financial Statements in accordance with GAAP for Taxes that
have accrued but are not yet due or payable as of the dates thereof.
(c) No claim has been made in writing by any taxing authority in the last three years in any
jurisdiction where the Company or any of the Company Affiliates does not file Returns that it is or
may be subject to material Tax by that jurisdiction.
26
(d) No claim for assessment or collection of material Taxes is presently being asserted
against the Company or any of the Company Affiliates, there is no presently pending audit
examination, request for information, refund claim, litigation, proceeding, proposed adjustment or
matter in controversy with respect to any material Taxes of or with respect to the Company or any
of the Company Affiliates.
(e) There are no Encumbrances for material Taxes, other than Encumbrances for current Taxes
not yet due and payable, upon the assets of the Company or any of the Company Affiliates.
(f) Neither the Company nor any of the Company Affiliates is a party to or bound by any tax
indemnity, tax sharing or tax allocation agreement.
(g) Neither the Company nor any Company Affiliate is a party to or bound by any closing
agreement, offer in compromise, or any other agreement with any taxing authority.
(h) Neither the Company nor any of the Company Affiliates has been a member of an affiliated
group of corporations, within the meaning of Section 1504 of the Code, or a member of a combined,
consolidated or unitary group for state, local or foreign Tax purposes, other than a group of which
the Company is the common parent. Neither the Company nor any of the Company Affiliates has any
liability for Taxes of any Person other than the Company and the Company Affiliates under Treasury
Regulations Section 1.1502-6 or any corresponding provision of state, local or foreign income Tax
Law, as transferee or successor, by Contract or otherwise.
(i) Each of the Company and the Company Affiliates has at all times used the accrual method of
accounting for income Tax purposes.
(j) Neither the Company nor any of its Subsidiaries is a party to any Contract or plan that
has resulted or would result, separately or in the aggregate, in connection with the transactions
contemplated by this Agreement, in the payment of any “excess parachute payments” within the
meaning of Section 280G of the Code.
(k) Neither the Company nor any Company Affiliate holds an interest in an entity that is not
organized under the laws of the United States or is subject to Tax in a jurisdiction other than the
United States.
(l) Neither the Company nor any of the Company Affiliates is, or has been, a United States
real property holding corporation, as defined in Section 897(c)(2) of the Code, during the
applicable period specified in Section 897(c)(1)(a) of the Code.
(m) There is currently no limitation on the utilization of material net operating losses,
capital losses, built-in losses, tax credits or similar items of the Company or any of its
Subsidiaries under Sections 269, 382, 383, 384 or 1502 of the Code and the Treasury Regulations
thereunder and comparable provisions of state, local or foreign Law.
27
(n) Neither the Company nor any of the Company Affiliates has been a “distributing
corporation” or a “controlled corporation” in connection with a distribution described in Section
355 of the Code.
(o) The Company has not engaged in a transaction that constitutes a “reportable transaction”
as defined in Treasury Regulation Section 1.6011-4(b).
(p) There is no taxable income of the Company or the Company Affiliates that is required under
applicable Tax law to be reported by the Company or the Company Affiliates for a taxable period
beginning after the Closing Date which taxable income was realized (and reflects economic income
arising) prior to the Closing Date or relates to a transaction that occurred prior to the Closing
Date, including as a result of (i) change in method of accounting pursuant to Section 481(a) of the
Code or any similar provision of Law, (ii) “closing agreement” as described in Section 7121 of the
Code (or any corresponding or similar provision of state, local or foreign income Tax Law) executed
on or prior to the Closing Date, (iii) installment sale or open transaction disposition made on or
prior to the Closing Date or (iv) prepaid amount received on or prior to the Closing Date.
(q) Since December 31, 2003, there has been no indebtedness at Coram Healthcare Corporation
that has been discharged or settled for an amount below the face amount of the debt or otherwise at
a discount in a manner that would result in attribute reduction under Section 108(b) of the Code.
(r) Coram Healthcare Corporation has timely paid all material Taxes that have become due or
payable (whether or not shown on a Return) and will not be subject to any material Taxes after the
Closing Date as a result of an agreement entered into prior to the Closing
Date or an event or transaction that has occurred prior to the Closing Date for which the
Company is responsible.
Section 3.18 Environmental Matters.
(a) Since October 1, 2003, (i) each of the Company and the Company Affiliates is and has been
in compliance with all applicable Environmental Laws and (ii) none of the Company, any of the
Company Affiliates or any of its or their executive officers has received any communication, demand
or complaint from a Governmental Authority or other Person alleging that the Company or any of the
Company Affiliates has any liability, or investigatory, corrective, or remedial obligation, under
any Environmental Law or is not in compliance with any Environmental Law, except where such
non-compliance, individually or in the aggregate, has not had and would not reasonably be expected
to have a Material Adverse Effect.
(b) To the knowledge of the Company, there is and has been no Release or threatened Release of
Hazardous Substances nor any clean-up or corrective action of any kind relating thereto, on any
properties (including any buildings, structures, improvements, soils and surface, subsurface and
ground waters thereof) currently or formerly owned, leased or operated by or for the Company or any
of the Company Affiliates or any predecessor company or at any other location with respect to which
the Company or any of the Company Affiliates may be liable. No underground improvement, including
any treatment or storage tank or water, gas or
28
oil well, is or has been located on any property
described in the foregoing sentence. To the knowledge of the Company, neither the Company nor any
of the Company Affiliates is actually, contingently, potentially or allegedly liable for any
Release of, threatened Release of or contamination by Hazardous Substances or otherwise under any
Environmental Law. There is no pending or, to the knowledge of the Company, threatened
investigation by any Governmental Authority, nor any pending or, to the knowledge of the Company,
threatened Action, with respect to the Company or any of the Company Affiliates under any
Environmental Law. The Company has not agreed to assume, undertake or provide indemnification for
any liability of any other person under any Environmental Laws, including any obligation for
corrective or remedial action.
(c) The Company and the Company Affiliates have provided to the Acquiror all “Phase I,” “Phase
II” or other environmental assessment reports in their possession or to which they have reasonable
access addressing locations ever owned, operated or leased by the Company or any of the Company
Affiliates or at which the Company or any of the Company Affiliates actually, potentially or
allegedly may have liability under any Environmental Law.
Section 3.19 Material Contracts.
(a) Section 3.19(a) of the Disclosure Letter sets forth any Contract of the following nature
that either the Company or any of the Company Affiliates is a party to or is bound and that is
outstanding or in effect on the date of this Agreement (such Contracts as are
required to be set forth in Section 3.19(a) of the Disclosure Letter being “Material
Contracts”):
(i) any material broker, distributor, dealer, manufacturer’s representative, franchise,
agency, continuing sales or continuing purchase, sales promotion, market research, marketing
or consulting Contract;
(ii) any Contract relating to or evidencing indebtedness of the Company or any of the
Company Affiliates including mortgages, other grants of security interests, guarantees or
notes;
(iii) any Contract pursuant to which the Company or any of the Company Affiliates has
provided funds to or made any loan, capital contribution or other investment in, or assumed
any liability or obligation of, any Person, including take-or-pay Contracts or keepwell
agreements;
(iv) any Contract for the acquisition or disposition, directly or indirectly (by merger
or otherwise), of capital stock or other equity interests of any Person or of any business
or business organization or any division or business unit thereof;
(v) any acquisition Contract pursuant to which the Company or any of the Company
Affiliates has continuing indemnification, “earn-out” or other contingent payment
obligations;
29
(vi) any Contract with any of the top 25 payors of the Company and the Company
Affiliates (determined on the basis of revenues) for the twelve month period ended June 30,
2007;
(vii) any Contract with any of the top 25 suppliers of the Company and the Company
Affiliates (determined on the basis of payables to such suppliers) for the twelve month
period ended June 30, 2007;
(viii) any Contract with any Related Party of the Company or any of the Company
Affiliates;
(ix) any Governmental Agreement;
(x) any employment or consulting Contract requiring aggregate annual payments in excess
of $100,000;
(xi) any Contract that limits, or purports to limit, the ability of the Company or any
of the Company Affiliates to compete in any material line of business or with any Person or
in any material geographic area or during any period of time, or that restricts the right of
the Company and the Company Affiliates to sell to or purchase from any Person or to hire any
Person, or that grants the other party or any third person “most favored nation” status;
(xii) any Contract that requires a consent to or otherwise contains a provision
relating to a “change of control” in either case that would prohibit or delay the
consummation of the transactions contemplated by this Agreement;
(xiii) any Contract pursuant to which the Company or any of the Company Affiliates is
the lessee or lessor of, or holds, uses, or makes available for use to any Person (other
than the Company or any Company Affiliate), (A) any real property or (B) any tangible
personal property and, in the case of clause (B), requiring aggregate annual payments in
excess of $100,000;
(xiv) any Contract for the sale or purchase of any real property, or for the sale or
purchase of any tangible personal property in an amount in excess of $100,000;
(xv) any Contract providing for indemnification to or from any Person with respect to
liabilities relating to any current or former business of the Company, any of the Company
Affiliates, Cherry Healthcare Corporation or any predecessor Person, other than standard
form indemnities entered into in the ordinary course consistent with past practice;
(xvi) any Contract entered into in connection with a disposition of stock or material
assets that contains confidentiality clauses;
(xvii) any Contract relating in whole or in part to any material Intellectual Property
(other than standard licenses for commercially available software);
30
(xviii) any joint venture or partnership agreement;
(xix) any merger, asset or stock purchase or divestiture Contract relating to the
Company or any of the Company Affiliates that contains representations, covenants,
indemnities or other obligations that are still in effect;
(xx) any Contract with any labor union or providing for benefits under any Plan;
(xxi) any Contract for the purchase of any debt or equity security or other ownership
interest of any Person, or for the issuance of any debt or equity security or other
ownership interest, or the conversion of any obligation, instrument or security into debt or
equity securities or other ownership interests of, the Company or any of the Company
Affiliates;
(xxii) any Contract relating to settlement of any administrative or judicial
proceedings entered into within the last three years;
(xxiii) any Contract, arrangement or other instrument relating to off-balance sheet
arrangements, loss sharing or loss guarantee and contingent purchase transactions, special
purpose entity transactions or other similar transactions of the Company or any of the
Company Affiliates, and all obligations assumed by the Company
or any of the Company Affiliates under interest rate or currency hedging or swap
transactions or any other derivative transaction; or
(xxiv) any other Contract, whether or not made in the ordinary course of business (A)
that requires aggregate annual payments in excess of $250,000, (B) that has a term greater
than one year and cannot be cancelled by the Company or a Company Affiliate without penalty
or further payment and without more than 180 days’ notice or (C) the loss of which would
result in a Material Adverse Effect.
(b) Each Material Contract is a legal, valid, binding and enforceable agreement and is in full
force and effect, except where the failure to be legal, valid, binding and enforceable,
individually or in the aggregate, has not had and would not reasonably be expected to have a
Material Adverse Effect. None of the Company or any of the Company Affiliates or, to the knowledge
of the Company, any other party is in breach or violation of, or (with or without notice or lapse
of time or both) default under, any Material Contract (except for breaches, violations or defaults
that, individually or in the aggregate, has not had and would not reasonably be expected to have a
Material Adverse Effect), nor has the Company or any of the Company Affiliates received any claim
of any such breach, violation or default. The Company has delivered or made available to the
Acquiror true and complete copies of all Material Contracts, including any material amendments
thereto.
Section 3.20 Affiliate Interests and Transactions.
(a) No Related Party of the Company or any of the Company Affiliates: (i) has or has had any
business dealings or a financial interest in any transaction with the Company or any of the Company
Affiliates or involving any assets or property of the Company
31
or any of the Company Affiliates,
other than business dealings or transactions conducted in the ordinary course of business
consistent with past practice at prevailing market prices and on prevailing market terms; or (ii)
is or has been employed by the Company or any of the Company Affiliates.
(b) There are no outstanding notes payable to, accounts receivable from or advances by the
Company or any of the Company Affiliates to, and neither the Company nor any of the Company
Affiliates is otherwise a debtor or creditor of, or has any liability or other obligation of any
nature to, any Related Party of the Company or any of the Company Affiliates. Since June 30, 2007,
neither the Company nor any of the Company Affiliates has incurred any obligation or liability to,
or entered into or agreed to enter into any transaction with or for the benefit of, any Related
Party of the Company or any of the Company Affiliates, other than the transactions contemplated by
this Agreement.
Section 3.21 Insurance. The Company maintains for itself and the Company Affiliates policies covering the assets,
business, equipment, properties, operations, employees, directors and officers, and product
warranty and liability claims, and such other forms of insurance in such amounts, with such
deductibles and against such risks and losses as, in its good faith judgment, are reasonable for
the business and assets of the Company and the Company Affiliates. All such
policies are in full force and effect and were in full force and effect during the periods of
time such insurance policies are purported to have been or be in effect, and neither the Company
nor any of the Company Affiliates is in material breach or default (including any such breach or
default with respect to the payment of premiums or the giving of notice), and no event has occurred
which, with notice or the lapse of time, would constitute such a material breach or default, or
permit termination or modification, under any such policy. There is no claim by the Company or any
of the Company Affiliates pending under any such policies that (a) has been denied or disputed by
the insurer other than denials and disputes in the ordinary course of business consistent with past
practice or (b) if not paid would reasonably be expected to have a Material Adverse Effect.
Section 3.22 Brokers. Except for MTS Health Partners, LP, the fees of which will be paid by the Company and
included as Transaction Expenses, no broker, finder or investment banker is entitled to any
brokerage, finder’s or other fee or commission in connection with the transactions contemplated
hereby based upon arrangements made by or on behalf of the Company or any of the Company
Affiliates. The Company has furnished to the Acquiror a complete and correct copy of all
agreements between the Company and MTS Health Partners, LP pursuant to which such firm would be
entitled to any payment relating to the transactions contemplated hereby.
Section 3.23 Health Care Matters. Except for matters, individually or in the aggregate, as have not had, and would not
reasonably be expected to have, a Material Adverse Effect:
(a) The Company, the Company Affiliates and, to the knowledge of the Company, their respective
directors, officers, employees and agents (while acting in such capacity), are and have been in
compliance with all Laws, including all Health Care Laws. None of the Company or the Company
Affiliates have received notice of, and there are no pending or, to the knowledge of the Company,
threatened legal proceedings relating to non-compliance by,
32
or liability of, the Company or the
Company Affiliates under any Law, including any Health Care Law.
(b) Section 3.23(b) of the Disclosure Letter sets forth a complete list of the Health Care
Permits. The Company and the Company Affiliates have (i) all Health Care Permits, (ii) not
received notice and have no knowledge that any Governmental Authority is considering limiting,
suspending, terminating, adversely amending or revoking any such Health Care Permit, and (iii) not
received notice of any deficiencies requiring corrective action plans that have not been completed
and accepted by the Governmental Authority. All such Health Care Permits are valid and in full
force and effect and the Company and the Company Affiliates are in compliance with the terms and
conditions of all such Health Care Permits and with the applicable Health Care Laws and rules and
regulations of the Governmental Authorities having jurisdiction with respect to such Health Care
Permits.
(c) The Company and the Company Affiliates meet all of the requirements of participation and
payment of, and where applicable are parties to valid supplier or other
participation agreements for payment by, Medicare, Medicaid, any other state or federal
government health care programs, any private insurance company, health maintenance organization,
preferred provider organization, managed care organization, government contracting agency, or any
other public or private third party payor program (“Programs”) to the extent they xxxx or
receive reimbursement from a particular Program. There are no legal proceedings pending or, to the
knowledge of the Company, threatened which would be reasonably likely to result in a revocation,
suspension, termination, probation, restriction, limitation, or non-renewal of any Program supplier
or other participation agreement or result in the exclusion of the Company, any of the Company
Affiliates or any of their respective directors, officers, employees or agents from any Program.
None of the Company, the Company Affiliates, nor, to the knowledge of the Company, their respective
officers, directors or managing employees have engaged in any activities which are cause for civil
penalties or mandatory or permissive exclusion from any Program.
(d) To the knowledge of the Company, all reports, documents, claims, applications, and notices
required to be filed, maintained or furnished to any Governmental Authority, including all
information required to be filed under any Program, have been so filed, maintained or furnished and
all such reports, documents, claims, applications and notices were complete and correct in all
material respects on the date filed (or were corrected or supplemented by a subsequent filing).
Section 3.24 Inspections and Investigations. (a) Neither the Company’s nor any of its Subsidiaries’ rights, nor, to the knowledge of the
Company, the right of any entity set forth on Section 1.1(a) of the Disclosure Letter or any
licensed professional or other individual employed by the Company or any Company Affiliate, to
receive reimbursements pursuant to any Government Program or Private Program has been terminated,
suspended or materially limited as a result of any investigation or action whether by any federal
or state governmental regulatory authority or other third party; and (b) neither the Company nor
any Company Affiliate has, during the past six years, been the subject of any non-ordinary course
inspection, investigation, survey, audit, monitoring or other form of review by any governmental
regulatory entity, professional review organization, accrediting organization or certifying agency
based upon any
33
alleged improper activity, nor has the Company nor any Company Affiliate received
any notice of deficiency (other than those that have been cured or for which a plan of correction
has been or will be submitted and is or will be under implementation) during the past ten years in
connection with the operations of its business.
Section 3.25 Rates and Reimbursements. The Company does not have any non-ordinary course reimbursement or payment rate appeals,
disputes or contested positions currently pending before any Governmental Authority or any
administrator of any Private Programs.
Section 3.26 Regulatory Matters.
(a) The Company and the Company Affiliates hold all material licenses and other material
rights, accreditations, permits and authorizations required by law, ordinance,
regulation or ruling of any Governmental Authority necessary to operate their businesses. The
Company and the Company Affiliates are certified for participation and reimbursement under Titles
XVIII and XIX of the Social Security Act and have current provider agreements for such Government
Programs and with such Private Programs, including any private insurance program under which they
directly or indirectly are presently receiving payments. Set forth in Section 3.26(a) of the
Disclosure Letter is a correct and complete list in all material respects, with respect to the
Company and the Company Affiliates, of such licenses and provider numbers under all Government
Programs.
(b) No material violation, default, order or deficiency exists with respect to any material
licenses and other material rights, accreditations, permits and authorizations required by law
(collectively, the “Rights”), ordinance, regulation or ruling of any Governmental Authority
necessary to operate the Company’s and the Company Affiliates’ businesses in all material respects
as presently operated. The Company has not received any written notice of any action pending or
recommended by any state or federal agencies having jurisdiction over such Rights, either to
revoke, withdraw or suspend any license, right or authorization, or to terminate the participation
of the Company or any of the Company Affiliates in any Government or Private Program. Since
September 30, 2004, the Company has renewed or intends to renew, and has not received any notice or
communication from the other party of an intent to terminate or not renew, each provider or
third-party payer agreement of the Company necessary for the operation of the Business.
(c) Except, individually or in the aggregate, as have not had, and would not reasonably be
expected to have, a Material Adverse Effect, the Company and the Company Affiliates have timely
filed all reports required to be filed and timely filed all claims or xxxxxxxx prior to the date
hereof in accordance with the Government and Private Programs, all fiscal intermediaries and other
insurance carriers and all such reports and xxxxxxxx are complete and accurate in all material
respects and have been prepared in compliance in all material respects with all applicable laws,
rules and regulations governing reimbursement and payment claims. The Company and the Company
Affiliates have paid or caused to be paid all known and undisputed refunds, overpayments, discounts
or adjustments which have become due pursuant to such reports and xxxxxxxx including any hospice
Medicare cap liability and to the knowledge of the Company have no liability under any Government
or Private Program (including, but not limited to any hospice Medicare cap liability) for any
refund, overpayment, discount or
34
adjustment. To the knowledge of the Company, there are no other
reports or claims or xxxxxxxx required to be filed by the Company in order to be paid under any
Government or Private Program for services rendered in connection with the business, except for
reports not yet due.
(d) Neither the Company nor any of the Company Affiliates nor any of their employees is a
party to, nor subject to, the terms of any corporate integrity agreement (“CIA”),
certificate of compliance agreement (“CCA”), monitoring agreement, consent decree,
settlement order, or similar agreement with or imposed by any Governmental Authority (collectively,
“Governmental Agreements”).
(e) Except as permitted under applicable Laws, to the knowledge of the Company, neither the
Company nor any of the Company Affiliates have: (i) offered, paid,
solicited or received anything of value, paid directly or indirectly, overtly or covertly, in
cash or in-kind (including any kick-back, self referral, bribe, or rebate) (collectively,
“Remuneration”) to or from any physician or actual or potential referral source, family
member of a physician or actual or potential referral source, or an entity in which a physician or
actual or potential referral source or physician family member or actual or potential referral
source family member has an ownership or investment interest, including:(A) payments for personal
or management services pursuant to a medical director agreement, consulting agreement, management
contract, personal services agreement, or otherwise; (B) payments for the use of premises leased to
or from a physician, a family member of a physician or an entity in which a physician or actual or
potential referral source or family member has an ownership or investment interest; or (C) payments
for the acquisition or lease of equipment, goods or supplies from a physician or actual or
potential referral source, a family member of a physician or actual or potential referral source or
an entity in which any of them has an ownership or investment interest; (ii) except for lawful
discounts offered in the ordinary course of business consistent with industry practice, offered,
paid, solicited or received any Remuneration (excluding fair market value payments for equipment or
supplies) to or from any health care provider, pharmacy, drug or equipment supplier, distributor or
manufacturer, including discounts, rebates, or other reductions in price on a good or service
received by the Company or any of the Company Affiliates; (iii) except for lawful discounts offered
in the ordinary course of business consistent with industry practice, offered, paid, solicited or
received any Remuneration to or from any person or entity in order to induce business, including
payments intended not only to induce actual or potential referrals of patients, but also to induce
the purchasing, leasing, ordering or arrangement for any good, facility, service or item; (iv)
entered into any financial relationships within the meaning of 42 C.F.R. § 411.354; including any
joint venture, partnership, co-ownership or other arrangement involving any ownership or investment
interest by any physician, or family member of a physician, or an entity in which physician or
physician family member has an ownership or investment interest, directly or indirectly, through
equity, debt, or other means, including an interest in an entity providing goods or services to the
Company or any of the Company Affiliates; (v) entered into any compensation arrangement or business
venture, including any joint venture, partnership, co-ownership or other arrangement involving any
ownership or investment interest by any person or entity including a hospital, pharmacy, drug or
equipment supplier, distributor or manufacturer, that is or was in a position to make or influence
actual or potential referrals, furnish items or services to, or otherwise generate business for the
Company or the Company Affiliates; or (vi) entered into any agreement providing for the actual or
potential referral of any patient for the provision of goods or services by the Company or the
Company Affiliates, or payments by the
35
Company or any of the Company Affiliates as a result of any
referrals of patients to a Company (excluding commercial payer Contracts providing for such
referrals and payments).
(f) To the knowledge of the Company, neither the Company nor any of the Company Affiliates nor
any independent contractor providing professional services on behalf of and in connection with the
Company and the Company Affiliates has engaged in any activities which are prohibited under 42
U.S.C. §§ 1320a-7b, 42 U.S.C. §§ 1395nn or 31 U.S.C. §§ 3729-3733 (or other federal or state
statutes related to false or fraudulent claims) or the regulations promulgated thereunder pursuant
to such statutes, or similar state or local statutes or regulations, or which are prohibited by
rules of professional conduct, including the following: (i) knowingly and willfully making or
causing to be made a false statement or representation of a material fact
in any application for any benefit or payment; (ii) knowingly and willfully submitting claims
for services when such services did not fully satisfy any conditions for payment; (iii) knowingly
and willfully making or causing to be made any false statement or representation of a material fact
for use in determining rights to any benefit or payment; (iv) failing to disclose knowledge by a
claimant of the occurrence of any event affecting the initial or continued right to any benefit or
payment on its own behalf or on behalf of another, with intent to fraudulently secure such benefit
or payment; (v) billing for referrals from physicians with a financial relationship with the
Company or any of the Company Affiliates that does not meet an exception; and (vi) knowingly and
willfully soliciting or receiving any Remuneration, directly or indirectly, overtly or covertly, in
cash or in-kind or paying or offering to pay or receive such remuneration (A) in return for
referring an individual to a person for the furnishing or arranging for the furnishing of any item
or service for which payment may be made in whole or in part by Medicare or Medicaid, or (B) in
return for purchasing, leasing, or ordering or arranging for or recommending purchasing, leasing,
or ordering any good, facility, service or item for which payment may be made in whole or in part
by Medicare or Medicaid.
(g) To the knowledge of the Company, neither the Company nor any of the Company Affiliates
have engaged in any activities which are prohibited under the Federal Controlled Substances Act,
the Federal Food, Drug and Cosmetic Act, or the regulations promulgated pursuant to such statutes
or any similar state or local statutes or regulations concerning the dispensing and sale of
controlled substances.
(h) To the knowledge of the Company, neither the Company nor any of the Company Affiliates
nor, to the knowledge of the Company, any of their respective officers, directors, employees, or
agents or persons who provide professional services to the Company or any Company Affiliate, has,
in connection with activities directly or indirectly related to the Company or such Company
Affiliate, engaged in any activities which are prohibited under the Federal Controlled Substances
Act, the Federal Food, Drug and Cosmetic Act, or the regulations promulgated pursuant to such
statutes or any similar state or local statutes or regulations concerning the dispensing and sale
of controlled substances.
(i) The Company and each of the Company Affiliates: (i) is in material compliance with all
applicable Laws and any other applicable guidance relating to the operation of each of its
pharmacies, the repackaging of drug products, the wholesale distribution of prescription drugs or
controlled substances, and the dispensing of prescription drugs or controlled substances; (ii) is
in compliance with all applicable Laws and any other applicable
36
guidance relating to the labeling,
packaging, advertising, or adulteration of prescription drugs or controlled substances; and (iii)
is not subject to any sanction or other adverse action by any Governmental Authority for the
matters described above in clauses (i) and (ii).
Section 3.27 Inventory. The inventory of the Company and the Company Affiliates in all material respects consists
of items of a quality and quantity usable and saleable in the ordinary course of business. The
amount and quality of the inventory of the Company and the Company Affiliates is consistent in all
material respects with normal operating levels maintained by the Company and the Company Affiliates
in the ordinary course of business.
ARTICLE IV
REPRESENTATIONS AND WARRANTIES OF THE ACQUIROR AND MERGER SUB
REPRESENTATIONS AND WARRANTIES OF THE ACQUIROR AND MERGER SUB
The Acquiror and Merger Sub hereby represent and warrant to the Company as follows:
Section 4.1 Organization
. Each of the Acquiror and Merger Sub is a corporation duly organized, validly existing and
in good standing under the laws of the State of Delaware and has full corporate power and authority
to own, lease and operate its properties and to carry on its business as it is now being conducted.
Section 4.2 Authority. Each of the Acquiror and Merger Sub has full corporate power and authority to execute and
deliver this Agreement, to perform its obligations hereunder and to consummate the transactions
contemplated hereby. The execution, delivery and performance by the Acquiror and Merger Sub of
this Agreement and the consummation by the Acquiror and Merger Sub of the transactions contemplated
hereby have been duly and validly authorized by the Boards of Directors of the Acquiror and Merger
Sub and by the Acquiror as the sole stockholder of Merger Sub. No other corporate proceedings on
the part of the Acquiror or Merger Sub are necessary to authorize the execution, delivery or
performance of this Agreement by the Acquiror or Merger Sub or for Acquiror or Merger Sub to
consummate the transactions contemplated hereby. This Agreement has been duly and validly executed
and delivered by the Acquiror and Merger Sub. This Agreement constitutes the legal, valid and
binding obligations of the Acquiror and Merger Sub enforceable against the Acquiror and Merger Sub
in accordance with its terms.
Section 4.3 No Conflict; Required Filings and Consents.
(a) The execution, delivery and performance by each of the Acquiror and Merger Sub of this
Agreement and the consummation of the transactions contemplated hereby, do not and will not:
(i) conflict with or violate the certificate of incorporation or bylaws of the Acquiror
or Merger Sub;
(ii) conflict with or violate any Law applicable to the Acquiror or Merger Sub; or
(iii) result in any breach of, constitute a default (or an event that, with notice or
lapse of time or both, would become a default) under or require any consent of
37
any Person
pursuant to, any note, bond, mortgage, indenture, agreement, lease, license, permit,
franchise, instrument, obligation or other Contract to which the Acquiror or Merger Sub is a
party;
except for any such conflicts, violations, breaches, defaults or other occurrences that,
individually or in the aggregate, have not had and would not reasonably be expected to have a
material adverse effect on the ability of the Acquiror or Merger Sub to perform its obligations
under this Agreement.
(b) Neither the Acquiror nor Merger Sub is required to file, seek or obtain any notice,
authorization, approval, order, permit or consent of or with any Governmental Authority in
connection with the execution, delivery and performance by the Acquiror and Merger Sub of this
Agreement or the consummation of the transactions contemplated hereby, except for (i) the filing
and recordation of the Certificate of Merger with the Secretary of State of the State of Delaware
and such filings with Governmental Authorities to satisfy the applicable Laws of states in which
the Company and the Company Affiliates are qualified to do business, (ii) such filings and
approvals as may be required by any federal or state securities Laws, including compliance with any
applicable requirements of the Exchange Act, and (iii) compliance with any applicable requirements
of the HSR Act and any other applicable foreign Laws, antitrust, competition or merger control Laws
of any jurisdiction.
Section 4.4 Financing. The Acquiror has, and on the Closing Date (prior to the Effective Time) shall have,
sufficient unrestricted funds on-hand in cash or available under its existing credit facility to
permit the Acquiror or Merger Sub to consummate the transactions contemplated by this Agreement,
including the Merger. Acquiror is a wholly owned direct or indirect subsidiary of Apria Healthcare
Group Inc. (“AHG”). AHG operates substantially all of its business through Acquiror and
its Subsidiaries. Acquiror and its Subsidiaries hold not less than 75% of the assets reflected in
AHG’s condensed consolidated balance sheet filed in its Quarterly Report on Form 10-Q for the
period ended June 30, 2007 and not less than 75% of the assets that would be reflected on a
consolidated balance sheet of AHG and its Subsidiaries as of the date hereof.
Section 4.5 Brokers. Except for Credit Suisse Securities (USA) LLC, the fees of which will be paid by the
Acquiror, no broker, finder or investment banker is entitled to any brokerage, finder’s or other
fee or commission in connection with the transactions contemplated hereby based upon arrangements
made by or on behalf of the Acquiror or Merger Sub.
ARTICLE V
COVENANTS
COVENANTS
Section 5.1 Conduct of Business Prior to the Closing. Between the date of this Agreement and the Closing Date, unless the Acquiror shall
otherwise agree in writing (which consent shall not be unreasonably withheld or delayed), the
business of the Company and the Company Affiliates shall be conducted only in the ordinary course
of business consistent with past practice and the Company’s operating budget as provided to the
Acquiror; and the Company shall use, and shall cause each of the Company Affiliates to use,
commercially reasonable efforts to preserve substantially intact the business organization
and assets of the Company and the
38
Company Affiliates, keep available the services of the
current officers, employees and consultants of the Company and the Company Affiliates (without any
obligation to pay additional compensation) and preserve the current relationships of the Company
and the Company Affiliates with customers, suppliers and other persons with which the Company or
any of the Company Affiliates has significant business relations; provided,
however, that no action by the Company or the Company Affiliates with respect to matters
specifically addressed by clauses (a) through (t) below shall be deemed a breach of this sentence
unless such action would constitute a breach of such other provision. By way of amplification and
not limitation, between the date of this Agreement and the Closing Date, neither the Company nor
any of the Company Affiliates shall do, or propose to do, directly or indirectly, any of the
following without the prior written consent of the Acquiror (which consent shall not be
unreasonably withheld or delayed) except (i) as may be required by applicable Law, (ii) as may be
agreed in writing by Acquiror, (ii) as may be required or expressly contemplated by this Agreement
or (iii) as set forth in Section 5.1 of the Disclosure Letter:
(a) amend or otherwise change its certificate of incorporation or bylaws or equivalent
organizational documents;
(b) issue, sell, pledge, dispose of or otherwise subject to any Encumbrance (i) any shares of
capital stock of the Company or any of the Company Affiliates, or any options, warrants,
convertible securities or other rights of any kind to acquire any such shares, or any other
ownership interest in the Company or any of the Company Affiliates or (ii) any material properties
or assets of the Company or any of the Company Affiliates, other than sales or transfers of
inventory or accounts receivable in the ordinary course of business consistent with past practice;
(c) declare, set aside, make or pay any dividend or other distribution, payable in cash,
stock, property or otherwise, or make any other payment on or with respect to any of its capital
stock, except for dividends by any direct or indirect wholly owned Subsidiary of the Company to the
Company;
(d) reclassify, combine, split, subdivide or redeem, or purchase or otherwise acquire,
directly or indirectly, any of its capital stock or make any other change with respect to its
capital structure;
(e) acquire any corporation, partnership, limited liability company, other business
organization or division thereof or any material amount of assets, or enter into any joint venture,
strategic alliance, exclusive dealing, non-competition or similar Contract or arrangement;
(f) except for the Merger, adopt a plan of complete or partial liquidation, dissolution,
merger, consolidation, restructuring, recapitalization or other reorganization of the Company or
any of the Company Affiliates, or otherwise alter the Company’s or a Company Affiliate’s corporate
structure;
(g) incur any indebtedness for borrowed money or issue any debt securities or assume,
guarantee or endorse, or otherwise become responsible for, the obligations of any
39
Person, or make any loans or advances, except in the ordinary course of business consistent
with past practice; provided that in no event shall the Company or any of the Company
Affiliates (i) incur, assume or guarantee any long-term indebtedness for borrowed money or (ii)
make any optional repayment of any indebtedness for borrowed money;
(h) amend, waive, modify or consent to the early termination of any Material Contract, or
amend, waive, modify or consent to the early termination of the Company’s or any of the Company
Affiliates’ rights thereunder, or enter into any Contract other than in the ordinary course of
business consistent with past practice;
(i) authorize, or make any commitment with respect to, capital expenditures in excess of
$150,000 per month for the Company and the Company Affiliates taken as a whole;
(j) enter into any lease of real or personal property other than (i) renewals or replacements
of existing leases on terms in the aggregate no less favorable than those in the lease being
replaced or renewed, and (ii) leases involving a term of less than one year or rental obligations
not exceeding $250,000 per year in any single case or $500,000 in the aggregate;
(k) increase the compensation payable or to become payable or the benefits provided to its
directors, officers or employees, or grant any bonus, severance, change of control, golden
parachute or termination payment to, or pay, loan or advance any amount to, any director, officer
or employee of the Company or any of the Company Affiliates, or establish, adopt, enter into or
amend any Plan except for payment and/or provision of severance benefits to terminated employees in
the ordinary course of business consistent with past practice; provided that, the Company
may increase the compensation payable or to become payable or the benefits provided, in accordance
with normal merit and cost-of-living increases consistent with past practice, to employees of the
Company or any of the Company Affiliates who are not directors or officers and who receive less
than $175,000 in annual base salary from the Company or any of the Company Affiliates to the extent
that such increases represent no more than 5% individually or 3.5% in the aggregate of all such
employees receiving such increased compensation or benefits;
(l) enter into any Contract with any Related Party of the Company or any of the Company
Affiliates;
(m) make any change in any method of accounting or accounting practice or policy, except as
required by GAAP;
(n) make, revoke or modify any material Tax election, settle or compromise any material Tax
liability, enter into any agreement with any Tax authority regarding material Taxes, consent to any
extension or waiver of the limitation period applicable to any claim or assessment in respect of
material Taxes, or file any Return other than on a basis consistent with past practice, except as
required by changes in Law;
(o) pay, discharge or satisfy any claim, liability or obligation (absolute, accrued, asserted
or unasserted, contingent or otherwise), other than the payment, discharge or satisfaction, in the
ordinary course of business consistent with past practice, of liabilities reflected or reserved
against on the Balance Sheet or subsequently incurred in the ordinary course of business consistent
with past practice;
40
(p) cancel, compromise, waive or release any right or claim other than in the ordinary course
of business consistent with past practice;
(q) permit the lapse of any existing policy of insurance relating to the business or assets of
the Company and the Company Affiliates;
(r) permit the lapse of any right relating to Intellectual Property or any other intangible
asset used in the business of the Company or any of the Company Affiliates;
(s) commence or settle any material Action; or
(t) announce an intention, enter into any formal or informal agreement, or otherwise make a
commitment to do any of the foregoing.
Section 5.2 Access to Information. Subject to restrictions imposed by the HSR Act and other applicable Laws, from the date
hereof through the Closing Date, the Company and the Company Affiliates shall provide their full
cooperation to afford the Acquiror and its officers, directors, principals, employees, advisors,
auditors, agents, bankers and other representatives (including, in the case of the Acquiror, any
representatives of any financing sources) (collectively, “Representatives”) during normal
business hours and upon reasonable advance notice access (including for inspection and copying) to
the Company’s and the Company Affiliates’ books and records, properties, offices, plants and other
facilities, and to such financial, legal and operating data and other information, as the Acquiror
or such Representatives shall reasonably request (so long as such access does not interfere
unreasonably with the business or operations of the Company or the Company Affiliates), and will
instruct the Company’s and the Company Affiliates’ employees, counsel and financial advisors
reasonably to cooperate with the Acquiror and its Representatives. Subject to restrictions imposed
by the HSR Act and other applicable Laws, from the date hereof until the Closing Date, the Company
and the Company Affiliates will allow Acquiror and its Representatives to make all extracts and
copies of the books and records of the Company and the Company Affiliates as the Acquiror or such
Representatives shall reasonably request.
Section 5.3 Exclusivity. The Company agrees that between the date of this Agreement and the earlier of the Closing
and the termination of this Agreement, the Company shall not, and shall take all action necessary
to ensure that none of the Company Affiliates or any of their respective Affiliates and
Representatives shall (a) solicit, initiate, consider, encourage or accept any proposal or offer
than constitutes an Acquisition Proposal or (b) participate in any discussions, conversations,
negotiations or other communications regarding, or furnish to any other Person any information with
respect to, or otherwise cooperate in any way, assist or participate in, facilitate or encourage
the submission of, any proposal that constitutes, or could reasonably be expected to lead to, an
Acquisition Proposal. The Company immediately shall cease and cause to be terminated all existing
discussions, conversations, negotiations and other communications with any Persons conducted
heretofore with respect to any of the foregoing. The Company shall notify the Acquiror promptly,
but in any event within 24 hours, orally and in writing if any such
Acquisition Proposal, or any inquiry or other contact with any Person with respect thereto, is
made. Any such notice to the Acquiror shall indicate in reasonable detail the identity of the
Person making such Acquisition Proposal, inquiry or other contact and the terms
41
and conditions of such Acquisition Proposal, inquiry or other contact. The Company shall not, and shall cause the
Company Affiliates not to, release any Person from, or waive any provision of, any confidentiality
or standstill agreement to which the Company or any of the Company Affiliates is a party, without
the prior written consent of the Acquiror.
Section 5.4 Notification of Certain Matters.
(a) The Company shall give written notice to the Acquiror reasonably promptly after becoming
aware of (i) the occurrence or non-occurrence of any event, change, circumstance, effect or state
of facts the occurrence or non-occurrence of which would reasonably likely result in the
non-fulfillment of the conditions to the Acquiror’s and Merger Sub’s obligations set forth in
Sections 6.3(a), (b), (c) or (e), (ii) the occurrence or non-occurrence of any event, change,
circumstance, effect or state of facts the occurrence or non-occurrence of which would reasonably
likely render any representation or warranty of the Company contained in this Agreement, if made on
or immediately following the date of such event, (A) in the case of representations and warranties
qualified by “materiality” or “Material Adverse Effect”, untrue or inaccurate and (B) in the case
of all other representations and warranties, untrue or inaccurate in any material respect, (iii)
the occurrence of any event, change, circumstance, effect or state of facts that has had or is
reasonably likely to have a Material Adverse Effect, (iv) any failure of the Company or any of the
Company Affiliates to comply with or satisfy any covenant or agreement to be complied with or
satisfied by it hereunder or any event or condition which would reasonably likely result in the
non-fulfillment of the conditions to the Acquiror’s and Merger Sub’s obligations set forth in
Sections 6.3(a), (b) (c) or (e), (v) any notice or other communication received by the Company
from any Person alleging that the consent of such Person is or may be required to consummate the
transactions contemplated by this Agreement or (vi) any Action pending or threatened against a
party or the parties relating to the transactions contemplated by this Agreement.
(b) The Acquiror shall give written notice to the Company reasonably promptly after becoming
aware of (i) the occurrence or non-occurrence of any event, change, circumstance, effect or state
of facts the occurrence or non-occurrence of which would reasonably likely result in the
non-fulfillment of the conditions to the Company’s obligations set forth in Section 6.2, (ii) the
occurrence of any event, change, circumstance, effect or state of facts that is reasonably likely
to delay beyond the Termination Date (including any applicable extension thereof) or materially
impair the ability of the Acquiror or Merger Sub to consummate the Merger (including delivery of
the aggregate Merger Consideration) and the other transactions contemplated by this Agreement,
(iii) any failure of the Acquiror, Merger Sub or their respective Affiliates to comply in all
material respects with any covenant or agreement to be complied with by it hereunder or any event,
change, circumstance, effect or state of facts that would reasonably likely result in the
non-fulfillment of the conditions to the Company’s obligations set forth in Section 6.2, (iv) any
notice or other written communication from any Person alleging that the consent of such Person is
or may be required in connection with the consummation of the
transactions contemplated by this Agreement or (v) any Action pending or, to the Acquiror’s
knowledge, threatened in writing against a party or the parties relating to the transactions
contemplated by this Agreement.
42
Section 5.5 Takeover Statutes. If any state takeover statute or similar Law shall become applicable to the transactions
contemplated by this Agreement, the Company and its Board of Directors shall grant such approvals
and take such actions as are necessary so that the transactions contemplated hereby may be
consummated as promptly as practicable on the terms contemplated hereby and otherwise act to
eliminate the effects of such statute or regulation on the transactions contemplated hereby.
Section 5.6 Stock Option Plans. Prior to the Effective Time, the Company shall pass appropriate resolutions that (a) all
equity-based incentive plans shall terminate as of the Effective Time and (b) after the Effective
Time, the Company is not bound by any Option, preferred stock, or other equity-based right that
would entitle any Person, other than the Acquiror or its Affiliates, to beneficially own, or
receive any payments other than as contemplated by Section 2.9 in respect of, any capital stock of
the Company or the Surviving Corporation.
Section 5.7 Confidentiality. Each of the parties agree to continue to be bound by the terms of the confidentiality
agreement dated June 7, 2007, as amended, between the Acquiror and the Company (the
“Confidentiality Agreement”), which shall continue in full force and effect until the
Closing Date. If for any reason this Agreement is terminated prior to the Closing Date, the
Confidentiality Agreement shall nonetheless continue in full force and effect in accordance with
its terms.
Section 5.8 Reasonable Best Efforts.
(a) Subject to the terms and conditions set forth in this Agreement, each of the parties shall
use its reasonable best efforts to take, or cause to be taken, all action to do, or cause to be
done, and to assist and cooperate with the other parties in doing, all things necessary, proper or
advisable under applicable Law or otherwise to consummate and make effective the transactions
contemplated by this Agreement by December 15, 2007, or as promptly as practicable thereafter,
including (i) obtaining from Governmental Authorities and other Persons, including from third party
payors where such approval is required, all actions or non-actions, licenses, waivers, consents,
clearances, approvals, authorizations, qualifications, orders, and expirations or terminations of
waiting periods, as may be necessary for the consummation of the transactions contemplated by this
Agreement to avoid an action or proceeding by any Governmental Authority seeking to challenge
consummation of such transactions or the operation of the Business post-closing, (ii) obtaining
from Governmental Authorities all actions or non-actions, licenses, waivers, consents, clearances,
approvals, authorizations, qualifications, orders, and expirations or terminations of waiting
periods, as may be necessary for the consummation of the transactions contemplated by this
Agreement or the operation of the
Business post-closing, (iii) promptly make all necessary filings, and thereafter make any
other required submissions, with respect to this Agreement required under the HSR Act or any other
applicable Law and (iv) defending of any lawsuits or other legal proceedings, whether judicial or
administrative, challenging this Agreement and having vacated, lifted, reversed or overturned any
order, decree, ruling, judgment, injunction or other action (whether temporary, preliminary or
permanent) that is in effect and that enjoins, restrains, conditions, makes illegal or otherwise
restricts or prohibits the consummation of the transactions contemplated by this Agreement. In
furtherance and not in limitation of the foregoing, the Company shall permit the Acquiror (and the
Acquiror shall permit the Company) reasonably to participate in the defense and settlement
43
of any
claim, suit or cause of action relating to this Agreement, the Merger or the other transactions
contemplated hereby, and the Company (and the Acquiror) shall not settle or compromise any such
claim, suit or cause of action without the Acquiror’s (or the Company’s) prior written consent
(which consent shall not be unreasonably withheld or delayed).
(b) Subject to the terms and conditions herein provided and without limiting the foregoing,
the Company, Acquiror and Merger Sub shall (i) promptly, but in no event later than ten days after
the date hereof, file any and all required Notification and Report Forms under the HSR Act with
respect to the Merger and the other transactions contemplated by this Agreement, and use all
reasonable efforts to cause the expiration or termination of any applicable waiting periods under
the HSR Act, (ii) supply to any Governmental Authority as promptly as practicable any additional
information or documents that may be requested pursuant to any Law or by such Governmental
Authority and (iii) take, or cause to be taken, all other actions and do, or cause to be done, all
other things necessary, proper or advisable to consummate and make effective the transactions
contemplated by this Agreement, including taking (and, in the case of Acquiror or Merger Sub,
causing each of its affiliates to take) all such further action as may be necessary promptly to
resolve such objections, if any, as the United States Federal Trade Commission, the Antitrust
Division of the United States Department of Justice, state antitrust enforcement authorities or
competition authorities of any other nation or other jurisdiction or any other person may assert
under any Law with respect to the transactions contemplated hereby, and to avoid or eliminate each
and every impediment under any Law that may be asserted by any Governmental Authority with respect
to the Merger or the other transactions contemplated hereby so as to enable the Closing to occur as
soon as reasonably possible (and in any event no later than the Termination Date), including (A)
proposing, negotiating, committing to and effecting, by consent decree, hold separate order or
otherwise, the sale, divestiture or disposition of any assets or businesses of Acquiror or its
Subsidiaries or affiliates or of the Company or its Subsidiaries and (B) otherwise taking or
committing to take any actions that after the Closing Date would limit the freedom of Acquiror or
its Subsidiaries’ (including the Surviving Corporation’s) or affiliates’ freedom of action with
respect to, or its ability to retain, one or more of its or its Subsidiaries’ (including the
Surviving Corporation’s) businesses, product lines or assets, in each case as may be required in
order to avoid commencement of litigation by a Governmental Authority seeking the entry of, or to
effect the dissolution of, any injunction, temporary restraining order or other order in any suit
or proceeding which would otherwise have the effect of preventing the Closing, materially delaying
the Closing or delaying the Closing beyond the Termination Date; provided that neither the Company
nor any of its Subsidiaries shall become subject to, or consent or agree to or otherwise take any
action with respect to, any requirement, condition, understanding, agreement or order of a
Governmental Authority to sell, to hold separate or otherwise dispose of, or to conduct, restrict,
operate, invest or otherwise
change the assets or business of the Company or any of its affiliates, unless such
requirement, condition, understanding, agreement or order is binding on the Company only in the
event that the Closing occurs.
(c) Subject to applicable legal limitations and the instructions of any Governmental
Authority, the Company and Acquiror shall keep each other apprised of the status of matters
relating to the completion of the transactions contemplated by this Agreement, including promptly
furnishing the other with copies of notices or other communications received by the Company or
Acquiror, as the case may be, or any of their respective Subsidiaries, from
44
any third party and/or
any Governmental Authority with respect to such transactions. The Company and Acquiror shall
permit counsel for the other party reasonable opportunity to review in advance, and consider in
good faith the views of the other party in connection with, any proposed written communication to
any Governmental Authority. Each of the Company and Acquiror agrees not to participate in any
substantive meeting or discussion, either in person or by telephone, with any Governmental
Authority in connection with the proposed transactions unless it consults with the other party in
advance and, to the extent not prohibited by such Governmental Authority, gives the other party the
opportunity to attend and participate. Notwithstanding anything to the contrary in this Section
5.8(c), materials provided to the other party or its outside counsel may be redacted to remove any
estimate of the valuation of the Company, its business or its shares, or identifying other
potential acquirers.
(d) In furtherance and not in limitation of the covenants of the parties contained in this
Section 5.8, if any administrative or judicial action or proceeding, including any proceeding by a
private party, is instituted (or threatened to be instituted) challenging any transaction
contemplated by this Agreement as violative of any Law, each of the Company and Acquiror shall
cooperate in all respects with each other and shall use their respective reasonable best efforts to
contest and resist any such action or proceeding and to have vacated, lifted, reversed or
overturned any decree, judgment, injunction or other order, whether temporary, preliminary or
permanent, that is in effect and that prohibits, prevents or restricts consummation of the Merger
and the other transactions contemplated by this Agreement.
Section 5.9 Public Announcements. On and after the date hereof and through the Closing, the parties will use reasonable best
efforts to consult with each other before issuing any press release or making any public statements
primarily relating to this Agreement or the transactions contemplated hereby, except that no such
consultation shall be necessary to the extent disclosure may be required by applicable Law or any
listing agreement of any party hereto. The parties agree to issue a mutually acceptable joint
press release announcing this Agreement.
Section 5.10 Financing.
(a) On and after the date hereof and through the Closing Date, the Company shall provide to
Acquiror and Merger Sub, and shall cause the Company Affiliates to, and shall use its reasonable
best efforts to cause the respective officers, employees and advisors, including legal and
accounting, of the Company and the Company Affiliates to, provide to Acquiror and Merger Sub all
cooperation reasonably requested by Acquiror that is reasonably necessary,
proper or advisable in connection with the financing of the transactions contemplated by this
Agreement (during normal business hours and upon reasonable advance notice; and so long as not
unreasonably interfering with the business or operations of the Company or the Company Affiliates),
including: (i) participating in meetings, presentations, due diligence sessions and sessions with
rating agencies, as Acquiror may reasonably request; (ii) assisting the Acquiror with the
preparation of materials for rating agency presentations, bank information memoranda, and similar
documents necessary, proper or advisable in connection with such financing or amendments thereto,
all as Acquiror may reasonably request, provided, that any bank information memoranda or similar
document need not be prepared or issued by the Company or any Company Affiliate prior to the
Effective Time; (iii) furnishing Acquiror and Merger Sub
45
with (A) the financial and other
information regarding the Company and the Company Affiliates specified on Schedule 1, and (B) such
other financial and other information regarding the Company and the Company Affiliates as is
customary for bank financings as may be reasonably required and requested by Acquiror; provided
that, the parties agree that, anything in Article VI notwithstanding, compliance with clause
(iii)(B) of this paragraph shall not be a condition to any party’s obligation to consummate the
transactions contemplated by this Agreement; and (iv) execution of a customary representation
letter (which may be qualified or limited, as circumstances require) in respect of information
provided by the Company or the Company Affiliates in writing expressly for use in connection with
such financing or the syndication thereof, for the benefit of the arrangers of the financing and
lenders and proposed lenders to Acquiror and/or Merger Sub in such financing.
(b) Acquiror shall indemnify and hold harmless the Company and its Subsidiaries, directors,
officers, employees, representatives and advisors from and against any and all losses, damages,
claims, costs or expenses suffered or incurred by any of them in connection with cooperation
provided pursuant to this Section 5.10, the financing of the transactions contemplated by this
Agreement, and any information utilized in connection therewith, except to the extent that such
losses, damages, claims, costs or expenses, directly or indirectly, resulted from the (i) the
delivery of audited or unaudited financial statements of the Company, or (ii) the gross negligence
or willful misconduct of the Company or any of its Subsidiaries.
Section 5.11 Employees.
(a) For a period of 12 months following the Closing Date, Acquiror shall provide, or cause the
Company and each of its Subsidiaries to provide, to employees of the Company and its Subsidiaries
base salary, annual bonus opportunities, and benefits (other than equity-based compensation) that
in the aggregate are substantially similar to, the base salary, annual bonus opportunities and
benefits provided to employees of the Company and its Subsidiaries immediately prior to the
Effective Time; provided that employees of the Company will be provided with equity
compensation substantially similar to similarly situated employees of Acquiror; provided,
further, that no provision of this Section 5.11(a) shall give any employee of the Company
or any of its Subsidiaries any right to continued employment or impair in any way the right of
Acquiror, the Company or any of its Subsidiaries to terminate the employment of any employee.
Acquiror shall honor, or shall cause to be honored, the terms of all change in control, employment
and severance agreements of the Company and its Subsidiaries in accordance with their terms as in
effect immediately prior to the Effective Time, subject to the
amendment and termination provisions of such agreements. Acquiror hereby acknowledges and
agrees that the transactions contemplated by this Agreement shall constitute a “change in control,”
change of control” or similar term under each of the Plans. At the Effective Time or, to the
extent that the Company determines that it is required by Section 409A, on January 2, 2008, each of
the payments on Section 5.11 of the Disclosure Letter shall be paid in full.
(b) Acquiror shall provide, or cause the Company and each of its Subsidiaries to provide, all
current and former employees of the Company or any of its Subsidiaries full credit for purposes of
eligibility, vesting and benefit accrual (but not including accrual of benefits under any defined
benefit pension plan), under the employee benefit plans and arrangements maintained by Acquiror or
the Company, its Subsidiaries or Affiliates in which such employees participate after the Effective
Time, for such employees’ service with the Company, its
46
Subsidiaries or their respective Affiliates
or predecessors prior to such date to the extent such employee was credited for such service before
the Effective Time under any similar Plans, except as would result in a duplication of benefits.
(c) With respect to all welfare benefit plans maintained by Acquiror or the Company or its
Subsidiaries for the benefit of employees of the Company or any of its Subsidiaries on and after
the Effective Time, each of the Company and Acquiror shall, or shall cause the Company’s
Subsidiaries to (i) cause there to be waived any eligibility requirements or pre-existing condition
limitations and (ii) give effect, in determining any deductible and maximum out-of-pocket
limitations, to amounts paid by such employees with respect to similar plans maintained by the
Company or any of its Subsidiaries prior to the Effective Time
(d) For fiscal year 2007, the Company shall pay each Employee employed as of February 28, 2008
and participating as of immediately prior to the Effective Time in any Plan that is an annual bonus
plan (a “Bonus Plan”), each of which is listed on Section 5.11(d) of the Disclosure Letter
and has been provided to Acquiror, a bonus on February 28, 2008 equal to the amount determined in
accordance with the terms of the relevant Bonus Plan by a three-person committee that includes the
Chief Executive Officer of the Company as of immediately prior to the Effective Time, acting by a
majority vote, not to exceed the maximum amount payable under the relevant Bonus Plan, to be
payable to such Employee for such fiscal year based on the Company’s and the individual’s actual
performance for the 2007 fiscal year and the Company’s accruals on its financial statements with
respect to such bonuses, provided that (i) the aggregate amount to be allocated by such committee
and paid out by the Company shall be not less than 85% of budgeted amounts if EBITDA (determined in
accordance with the Company’s past practices) for the bonus period is $16.1 million, which
percentage shall increase linearly to be not less than 100% if EBITDA (determined in accordance
with the Company’s past practices) for the bonus period is $18 million or greater and (ii) in the
event that, at or following the Effective Time and before February 28, 2008, the Employee’s
employment shall be terminated by the Company without Cause (as defined below) or the Employee
shall terminate employment by reason of the Employee’s death or Disability (as defined below), the
Employee (or the Employee’s estate or representative, as applicable) shall be entitled to payment
of a bonus as if such Employee had remained employed through February 28, 2008. Company
performance in respect of calculations made under the Bonus Plans for the 2007 fiscal year shall be
calculated without taking into account any expenses or costs associated with or arising as a result
of transactions contemplated by this Agreement, and no bonuses for
the fiscal year in which the Effective Time occurs shall be subject to negative discretion by
the administrator for the Bonus Plan. “Cause” shall mean (i) an Employee’s conviction of a felony,
(ii) an Employee’s continued refusal to substantially perform his or her duties with the Company or
(iii) a willful violation of any of Acquiror’s material policies, which have been provided to the
Employee in advance of such violation. “Disability” has the meaning set forth in the Company’s
long term disability plan applicable to the Employee.
(e) In addition, for fiscal year 2007, Acquiror shall cause the Company to provide the Company
discretionary matching contribution under the Company’s Section 401(k) plan as described in the
resolutions adopted at the November 14, 2006 meeting of the Board of Directors of the Company.
47
Section 5.12 Indemnification and Insurance.
(a) The Acquiror and Merger Sub agree that all rights to exculpation, indemnification and
advancement of expenses now existing in favor of the current or former directors, officers or
employees, as the case may be, of the Company or the Company Affiliates as provided in their
respective certificates of incorporation or bylaws or other similar constituent documents or in any
agreement shall survive the Merger and shall continue in full force and effect. For a period of six
years from the Effective Time, the Surviving Corporation shall, and the Acquiror shall cause the
Surviving Corporation to, maintain in effect the exculpation, indemnification and advancement of
expenses provisions of the Company’s and any of the Company Affiliates’ certificates of
incorporation and bylaws or similar constituent documents as in effect immediately prior to the
Effective Time or in any indemnification agreements of the Company or the Company Affiliates with
any of their respective directors, officers or employees as in effect immediately prior to the
Effective Time, and shall not amend, repeal or otherwise modify any such provisions in any manner
that would adversely affect the rights thereunder of any individuals who at the Effective Time were
current or former directors, officers or employees of the Company or any of the Company Affiliates;
provided, however, that all rights to indemnification in respect of any actual or
threatened Action pending or asserted or any claim made within such period shall continue until the
disposition of such Action or resolution of such claim. From and after the Effective Time, the
Acquiror shall cause the Surviving Corporation and its Subsidiaries to honor, in accordance with
their respective terms, each of the covenants contained in this Section 5.12 without limit as to
time.
(b) From and after the Effective Time, the Surviving Corporation shall, and the Acquiror shall
cause the Surviving Corporation to, to the fullest extent permitted under applicable Law, indemnify
and hold harmless (and advance funds in respect of each of the foregoing) each current and former
director, officer or employee of the Company or any of the Company Affiliates (each, together with
such Person’s heirs, executors or administrators, an “Indemnified Party”) against any costs
or expenses (including advancing reasonable attorneys’ fees and expenses in advance of the final
disposition of any claim, suit, proceeding or investigation to each Indemnified Party to the
fullest extent permitted by Law), judgments, fines, losses, claims, damages, liabilities and
amounts paid in settlement in connection with any Action, arising out of, relating to or in
connection with any such Person’s service as a director or officer of the Company or any of the
Company Affiliates or services performed in connection with such Person’s serving as an officer or
director or other
fiduciary in any entity if such service was at the request or for the benefit of the Company,
in each case, at or prior to the Effective Time; provided, however, that the
Surviving Corporation shall not be liable for any settlement effected without the Surviving
Corporation’s prior written consent (which shall not be unreasonably withheld or delayed) and the
Surviving Corporation shall not be obligated to pay the fees and expenses of more than one counsel
(selected by a plurality of the applicable Indemnified Parties and reasonably satisfactory to the
Surviving Corporation) for all Indemnified Parties in any jurisdiction with respect to any single
such claim, action, suit, proceeding or investigation, unless the use of one counsel for such
Indemnified Parties would present such counsel with a conflict of interest that would make such
joint representation inappropriate. It shall be a condition to the advancement of any amounts to
be paid in respect of legal and other fees and expenses that the Surviving Corporation receive an
undertaking by the Indemnified Party to repay such legal and other fees and expenses paid in
advance if it is ultimately
48
determined that such Indemnified Party is not entitled to be
indemnified under applicable Law. In the event of any such Action, the Surviving Corporation shall
reasonably cooperate with the Indemnified Party in the defense of any such Action.
(c) The Company shall obtain prior to the Effective Time “tail” insurance policies with a
claims period of at least six years from the Effective Time with respect to directors’ and
officers’ liability insurance of the type and with an amount of coverage as are no less favorable
than those of the directors’ and officers’ liability insurance maintained as of the date hereof by
the Company and the Company Affiliates (the “Current Policies”), and with such other terms
as are no less favorable in the aggregate than those of the Current Policies; provided
that, in satisfying such obligation, the Company shall not be obligated to pay aggregate premiums
in excess of 300% of the aggregate per annum amount that the Company paid for such coverage under
the Current Policies in the last full year prior to the date hereof, it being understood and agreed
that the Acquiror and the Surviving Corporation shall nevertheless be obligated to provide such
coverage as may be obtained for such amount.
(d) The Acquiror shall cause the Surviving Corporation to pay all reasonable expenses,
including reasonable attorneys’ fees, that may be incurred by any Indemnified Party in enforcing
the indemnity and other obligations provided in this Section 5.12.
(e) The rights of each Indemnified Party hereunder shall be in addition to, and not in
limitation of, any other rights such Indemnified Party may have under the certificates of
incorporation or bylaws or other constituent documents of the Company or any of the Company
Affiliates or the Surviving Corporation, any other indemnification arrangement, the DGCL or
otherwise. The provisions of this Section 5.12 shall survive the consummation of the Merger and
expressly are intended to benefit, and are enforceable by, each of the Indemnified Parties.
(f) In the event the Surviving Corporation or any of its successors or assigns (i)
consolidates with or merges into any other Person and shall not be the continuing or surviving
corporation or entity in such consolidation or merger or (ii) transfers all or substantially all of
its properties and assets to any Person, then, and in either such case, proper provision shall be
made so that the successors and assigns of the Surviving Corporation shall assume the obligations
set forth in this Section 5.12.
Section 5.13 Section 280G Stockholder Approval. The Company shall use reasonable best efforts to have, prior to the Closing, submitted to a
vote of the Company’s stockholders for their determination in accordance with Section
280G(b)(5)(A)(ii) of the Code all payments or benefits to Xxxx X. Xxxxxxx, Xxxxxxxxxx Xxxxxxxx and
Xxxx Xxxx that, in the absence of such a vote, would reasonably be expected to result in the loss
of deduction with respect to such payments as a result of Section 280G of the Code such that, if
such a stockholder vote is taken, no such payments will be subject to the excise tax provided for
under Section 4999 of the Code.
ARTICLE VI
CONDITIONS TO CLOSING
CONDITIONS TO CLOSING
Section 6.1 General Conditions. The respective obligations of each party to consummate the transactions contemplated by
this Agreement shall be subject to the fulfillment,
49
at or prior to the Closing, of each of the
following conditions, any of which may, to the extent permitted by applicable Law, be waived in
writing by any party in its sole discretion (provided that such waiver shall only be
effective as to the obligations of such party):
(a) No Injunction or Prohibition. No statute, rule, regulation or order shall have
been enacted or temporary or permanent restraining order or preliminary or permanent injunction or
other order shall have been entered or issued, by any Governmental Authority, in each case that
prohibits the consummation of the Merger.
(b) Regulatory Approvals. Any waiting period (and any extension thereof) under the
HSR Act applicable to the Merger shall have expired or shall have been terminated.
Section 6.2 Conditions to Obligations of the Company. The obligations of the Company to consummate the transactions contemplated by this
Agreement shall be subject to the fulfillment, at or prior to the Closing, of the following
conditions, which may be waived in writing by the Company in its sole discretion:
(a) Representations, Warranties and Covenants. The representations and warranties of
the Acquiror and Merger Sub set forth in Section 4.4 shall have been true and correct on the date
hereof and on and as of the Closing Date as though made on the Closing Date; and the other
representations and warranties of the Acquiror and Merger Sub set forth in this Agreement shall
have been true and correct on the date hereof and, on and as of the Closing Date as though made on
the Closing Date (except to the extent that any representation or warranty expressly speaks as of
an earlier date, in which case it shall be true and correct as of such date) except where the
failure of such representations and warranties to be so true and correct has not had, and would
not, individually or in the aggregate, reasonably be expected to prevent, render illegal, or delay
beyond the Termination Date (including any applicable extension thereof) or materially impair the
ability of the Acquiror or Merger Sub to consummate the Merger (including delivery of the aggregate
Merger Consideration) and the other transactions contemplated by this Agreement. The Acquiror and
Merger Sub shall have performed in all material respects all obligations and agreements and shall
have complied in all material respects with all covenants and conditions required by this Agreement
to be performed or complied with
by them prior to or at the Closing. The Company shall have received from each of the Acquiror
and Merger Sub a certificate to the effect set forth in the preceding sentences, signed by a duly
authorized officer of each of the Acquiror and Merger Sub.
Section 6.3 Conditions to Obligations of the Acquiror and Merger Sub. The obligations of the Acquiror and Merger Sub to consummate the transactions contemplated
by this Agreement shall be subject to the fulfillment, at or prior to the Closing, of each of the
following conditions, any of which may be waived in writing by the Acquiror in its sole discretion:
(a) Representations, Warranties and Covenants. Subject to the preamble to Article
III, (i) the representations and warranties of the Company set forth in Sections 3.2 and 3.4 shall
have been true and correct in all respects (except in the case of Section 3.4 for de minimis
inaccuracies), in each case, at and as of the date of this Agreement and at and as of the Closing
Date as though made at and as of the Closing Date (except to the extent that any representation or
warranty expressly speaks as of an earlier date, in which case it shall be true and correct as of
50
such date); and (ii) the representations and warranties of the Company set forth in this Agreement,
other than those specified in clause (i) above, shall have been true and correct at and as of the
date of this Agreement and at and as of the Closing Date as though made at and as of the Closing
Date (except to the extent that any representation or warranty expressly speaks as of an earlier
date, in which case it shall be true and correct as of such date) except, with respect to this
clause (ii), for such failures to be true and correct which have not had, or would not reasonably
be expected to have, a Material Adverse Effect. The Company shall have performed in all material
respects all obligations and agreements and shall have complied in all material respects with all
covenants and conditions required by this Agreement to be performed or complied with by it prior to
or at the Closing, except with respect to Section 5.4. With respect to Section 5.4, the Company
shall have complied with its obligations thereunder except to the extent any failure to comply has
not had, and would not reasonably be expected to have, a Material Adverse Effect. The Acquiror
shall have received from the Company a certificate to the effect set forth in the preceding
sentences, signed by a duly authorized officer thereof.
(b) Stockholder Approval. The Company Stockholder Approval is in full force and
effect and has not been modified, rescinded or revoked in any manner that would render the Closing
or the Merger illegal, impermissible or ultra xxxxx.
(c) No Material Adverse Effect. There shall not have occurred and be continuing any
event, change, circumstance, effect or state of facts that, individually or in the aggregate, has
had or is reasonably likely to have a Material Adverse Effect.
(d) Consents and Approvals. The applications, authorizations, consents, orders or
approvals of the Governmental Authorities set forth in Schedule 2 shall have been received.
(e) Election Filed and Certification. The Company shall have filed or caused to have
been filed by November 14, 2007, on behalf of Coram Healthcare Corporation, the election referenced
in the private letter ruling dated October 1, 2007, issued by the Internal
Revenue Service to Coram Healthcare Corporation, such election shall be substantially in the
form of the election set forth in Schedule 3, and an officer of the Company shall have
certified as of the date such election is made and as of the Closing Date that, after reasonable
inquiry and consultation with Coram Healthcare Corporation’s and the Company’s tax advisors, Coram
Healthcare Corporation has a tax basis in the stock of the Company for federal income tax purposes
of at least $75,000,000 (after taking account of such election) as of December 1, 2004.
ARTICLE VII
SURVIVAL
SURVIVAL
Section 7.1 Survival of Representations, Warranties and Covenants. The representations and warranties of the Company, the Acquiror and Merger Sub contained in this
Agreement and any Disclosure Letter, certificate or other document delivered pursuant hereto or
thereto or in connection with the transactions contemplated hereby or thereby shall not survive the
Closing; provided, however, that all covenants and agreements contained herein
which by their terms contemplate actions or impose obligations following the Closing (including,
for the
51
avoidance of doubt, Sections 5.10(b), 5.11 and 5.12) shall survive the Closing and remain
in full force and effect in accordance with their terms.
ARTICLE VIII
TERMINATION
TERMINATION
Section 8.1 Termination. This Agreement may be terminated and the transactions contemplated hereby abandoned at any
time prior to the Effective Time:
(a) by the mutual written consent of the Acquiror and the Company;
(b) (i) by the Company, if the Acquiror or Merger Sub breaches or fails to perform in all
material respects any of its representations, warranties or covenants contained in this Agreement
and such breach or failure to perform (A) would give rise to the failure of a condition set forth
in Section 6.2, (B) cannot be or has not been cured within 30 days following delivery of written
notice of such breach or failure to perform and (C) has not been waived by the Company or (ii) by
the Acquiror, if the Company breaches or fails to perform in all material respects any of its
representations, warranties or covenants contained in this Agreement and such breach or failure to
perform (x) would give rise to the failure of a condition set forth in Section 6.3, (y) cannot be
or has not been cured within 30 days following delivery of written notice of such breach or failure
to perform and (z) has not been waived by the Acquiror;
(c) (i) by the Company, if any of the conditions set forth in Section 6.1 or Section 6.2 shall
have become incapable of fulfillment prior to the Termination Date or (ii) by the Acquiror, if any
of the conditions set forth in Section 6.1 or Section 6.3 shall have become incapable of
fulfillment prior to the Termination Date; provided, that the right to terminate this
Agreement pursuant to this Section 8.1(c) shall not be available if the failure of the party so
requesting termination to fulfill any obligation under this Agreement shall have been the cause of
the failure of such condition to be satisfied on or prior to such date;
(d) by either the Company or the Acquiror if the Merger shall not have been consummated by
April 30, 2008 (the “Termination Date”); provided, however, that the right
to terminate this Agreement under this Section 8.1(d) shall not be available if the failure of the
party so requesting termination to fulfill any obligation under this Agreement shall have been the
cause of the failure of the Merger to be consummated on or prior to such date; or
(e) by either the Company or the Acquiror in the event that any Governmental Authority shall
have issued an order, decree or ruling or taken any other action restraining, enjoining or
otherwise prohibiting the Merger and such order, decree, ruling or other action shall have become
final and nonappealable; provided, that the Acquiror and Merger Sub (if the Acquiror is so
requesting termination) or the Company (if it is so requesting termination), as the case may be,
shall have used their reasonable best efforts, in accordance with Section 5.9, to have such order,
decree, ruling or other action vacated.
The party seeking to terminate this Agreement pursuant to this Section 8.1 (other than Section
8.1(a)) shall give prompt written notice of such termination to the other party.
52
Section 8.2 Effect of Termination. In the event of termination of this Agreement as provided in Section 8.1, this Agreement
shall forthwith become void, provided that (a) Section 3.22 and Section 4.5 relating to
broker’s fees and finder’s fees, Section 5.10(b) relating to financing indemnities, Section 9.1
relating to fees and expenses, Section 9.5 relating to notices, Section 9.6 relating to
interpretation, Section 9.8 relating to third-party beneficiaries, Section 9.9 relating to
governing law, and this Section 8.2 shall survive termination and remain in full force and (b)
nothing herein shall relieve either party from liability for fraud, any breach of any covenant or
agreement in this Agreement, or any willful and material breach of any of the representations or
warranties of this Agreement.
ARTICLE IX
GENERAL PROVISIONS
GENERAL PROVISIONS
Section 9.1 Fees and Expenses. Except as otherwise provided herein, all fees and expenses incurred in connection with or
related to this Agreement and the transactions contemplated hereby shall be paid by the party
incurring such fees or expenses, whether or not such transactions are consummated;
provided, however, that (1) the Acquiror shall pay all of the HSR filing fees in
connection herewith and the Company shall reimburse the Acquiror for one-half of such fees, and (2)
the Acquiror shall pay any transfer taxes in connection herewith; provided,
further, that all of the Transaction Expenses shall be paid as provided in this Agreement.
In the event of termination of this Agreement, the obligation of each party to pay its own expenses
will be subject to any rights of such party arising from a breach of this Agreement by the other.
Section 9.2 Amendment and Modification. This Agreement may be amended, modified or supplemented by the parties by action taken or
authorized by their respective Boards of Directors at any time prior to the Closing Date
(notwithstanding any stockholder approval); provided, however, that after approval
of the transactions contemplated hereby by the stockholders of the Company, no amendment shall be
made which pursuant to applicable Law requires further approval by such stockholders without such
further approval. This Agreement may not be amended, modified or supplemented in any manner,
whether by course of conduct or otherwise, except by an instrument in writing signed on behalf of
each of the parties in interest at the time of the amendment.
Section 9.3 Extension. At any time prior to the Effective Time, the parties, by action taken or authorized by
their respective Boards of Directors, may, to the extent permitted by applicable Law, extend the
time for the performance of any of the obligations or other acts of the parties. Any agreement on
the part of a party to any such extension shall be valid only if set forth in a written instrument
executed and delivered by a duly authorized officer on behalf of such party.
Section 9.4 Waiver. At any time prior to the Effective Time, the parties may, by action taken or authorized by
their respective Boards of Directors, to the extent permitted by applicable Law, (a) waive any
inaccuracies in the representations and warranties of the other parties contained in this Agreement
or any document delivered pursuant hereto or (b) subject to applicable Law, waive compliance with
any of the agreements or conditions of the other parties contained herein. Any agreement on the
part of a party to any such waiver shall be valid only if
53
set forth in a written instrument
executed and delivered by a duly authorized officer on behalf of such party. No failure or delay
of any party in exercising any right or remedy hereunder shall operate as a waiver thereof, nor
shall any single or partial exercise of any such right or power, or any abandonment or
discontinuance of steps to enforce such right or power, or any course of conduct, preclude any
other or further exercise thereof or the exercise of any other right or power. The rights and
remedies of the parties hereunder are cumulative and are not exclusive of any rights or remedies
which they would otherwise have hereunder.
Section 9.5 Notices. All notices and other communications hereunder shall be in writing and delivered personally
or by facsimile or utilizing a next-day service by a nationally recognized next-day courier, and
shall be deemed duly given (a) on the date of delivery if delivered personally, or, if by
facsimile, upon written confirmation of receipt and (b) if delivered utilizing a next-day service
by a nationally recognized next-day courier on the first Business Day following the date of
dispatch. All notices hereunder shall be delivered to the addresses set forth below, or pursuant
to such other instructions as may be designated in writing pursuant to the provisions of this
Section 9.5 by the party to receive such notice:
(a)
|
if to the Acquiror, Merger Sub or the Surviving Corporation, to: Apria Healthcare, Inc. 00000 Xxxxxxxxxx Xxxxx Xxxx Xxxxxx, Xxxxxxxxxx 00000 Attention: General Counsel Facsimile: (000) 000-0000 with a copy (which shall not constitute notice) to: Xxxxxx, Xxxx & Xxxxxxxx LLP 000 Xxxxx Xxxxx Xxxxxx Xxx Xxxxxxx, Xxxxxxxxxx 00000 Attention: Xxxxxxx Xx Xxxx Facsimile: (000) 000-0000 |
|
(b)
|
if to Company, to: Coram, Inc. 0000 Xxxxxxxx, Xxxxx 000 Xxxxxx, Xxxxxxxx 00000 Attention: Xxxxxxx Xxxx Facsimile: (000) 000-0000 with a copy (which shall not constitute notice) to: Wachtell, Lipton Xxxxx & Xxxx 00 X. 00xx Xxxxxx Xxx Xxxx, Xxx Xxxx 00000 Attention: Xxxx Xxxxxx Facsimile: (000) 000-0000 |
54
Section 9.6 Interpretation. When a reference is made in this Agreement to a Section, Article or Exhibit such reference
shall be to a Section, Article or Exhibit of this Agreement unless otherwise indicated. The table
of contents and headings contained in this Agreement or in any Exhibit are for convenience of
reference purposes only and shall not affect in any way the meaning or interpretation of this
Agreement. All words used in this Agreement will be construed to be of such gender or number as
the circumstances require. Any capitalized terms used in any Exhibit but not otherwise defined
therein shall have the meaning as defined in this Agreement. All Exhibits annexed hereto or
referred to herein are hereby incorporated in and made a part of this Agreement as if set forth
herein. The word “including” and words of similar import when used in this Agreement will mean
“including, without limitation,” unless otherwise specified.
Section 9.7 Entire Agreement. This Agreement (including the Exhibits and Disclosure Letter hereto), and the
Confidentiality Agreement constitute the entire agreement, and supersede all prior written
agreements, arrangements, communications and understandings and all prior and
contemporaneous oral agreements, arrangements, communications and understandings among the
parties with respect to the subject matter hereof and thereof.
Section 9.8 No Third-Party Beneficiaries. Except (a) as provided in Section 5.12 and (b) for the provisions of Sections 2.7, 2.9 and
2.10 (which, from and after the Effective Time, shall be for the benefit of holders of Shares and
Options as of the Effective Time), nothing in this Agreement, express or implied, is intended to or
shall confer upon any Person other than the parties and their respective successors and permitted
assigns any legal or equitable right, benefit or remedy of any nature under or by reason of this
Agreement.
Section 9.9 Governing Law. This Agreement and all disputes or controversies arising out of or relating to this
Agreement or the transactions contemplated hereby shall be governed by, and construed in accordance
with, the internal laws of the State of Delaware, without regard to the laws of any other
jurisdiction that might be applied because of the conflicts of laws principles.
Section 9.10 Enforcement. The parties agree that irreparable damage would occur in the event that any of the
provisions of this Agreement were not performed in accordance with their specific terms or were
otherwise breached. Accordingly, each of the parties shall be entitled to specific performance of
the terms hereof, including an injunction or injunctions to prevent breaches of this Agreement and
to enforce specifically the terms and provisions of this Agreement exclusively in the Delaware
Court of Chancery or, in the event (but only in the event) that such court does not have subject
matter jurisdiction over such action, in the United States District Court for the District of
Delaware, this being in addition to any other remedy to which such party is entitled at law or in
equity. Each of the parties hereby further waives (a) any defense in any action for specific
performance that a remedy at law would be adequate and (b) any requirement under any law to post
security as a prerequisite to obtaining equitable relief.
Section 9.11 Assignment; Successors. Neither this Agreement nor any of the rights, interests or obligations under this Agreement
may be assigned or delegated, in whole or in part, by operation of law or otherwise, by any party
without the prior written consent of the Acquiror (in the case of an assignment by the Company) or
the Company (in the case of an assignment by the Acquiror or Merger Sub), and any such assignment
without such prior written consent shall
55
be null and void; provided, however, that
the Acquiror or Merger Sub may assign this Agreement to any Affiliate of the Acquiror without the
prior consent of the Company; provided further, that no assignment shall limit the
assignor’s obligations hereunder. Subject to the preceding sentence, this Agreement will be
binding upon, inure to the benefit of, and be enforceable by, the parties and their respective
successors and assigns.
Section 9.12 Currency. All references to “dollars” or “$” or “US$” in this Agreement refer to United States
dollars, which is the currency used for all purposes in this Agreement.
Section 9.13 Severability. Whenever possible, each provision or portion of any provision of this Agreement shall be
interpreted in such manner as to be effective and valid under applicable Law, but if any provision
or portion of any provision of this Agreement is held to be invalid, illegal or unenforceable in
any respect under any applicable Law or rule in any jurisdiction, such invalidity, illegality or
unenforceability shall not affect any other provision or portion of any provision in such
jurisdiction, and this Agreement shall be reformed, construed and enforced in such jurisdiction as
if such invalid, illegal or unenforceable provision or portion of any provision had never been
contained herein.
Section 9.14 Waiver of Jury Trial. EACH OF THE PARTIES TO THIS AGREEMENT HEREBY IRREVOCABLY WAIVES ALL RIGHT TO A TRIAL BY
JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE
TRANSACTIONS CONTEMPLATED HEREBY.
Section 9.15 Counterparts. This Agreement may be executed in two or more counterparts, all of which shall be
considered one and the same instrument and shall become effective when one or more counterparts
have been signed by each of the parties and delivered to the other party.
Section 9.16 Facsimile Signature. This Agreement may be executed by facsimile signature and a facsimile signature shall
constitute an original for all purposes.
Section 9.17 Time of Essence. Time is of the essence with regard to all dates and time periods set forth or referred to
in this Agreement.
Section 9.18 No Presumption Against Drafting Party. Each of the Acquiror, Merger Sub and the Company acknowledges that each party to this
Agreement has been represented by counsel in connection with this Agreement and the transactions
contemplated by this Agreement. Accordingly, any rule of law or any legal decision that would
require interpretation of any claimed ambiguities in this Agreement against the drafting party has
no application and is expressly waived.
[The remainder of this page is intentionally left blank.]
56
IN WITNESS WHEREOF, the parties have caused this Agreement to be executed as of the date first
written above by their respective officers thereunto duly authorized.
APRIA HEALTHCARE, INC. |
||||
By: | /s/ Xxxxxxxx X. Xxxxx | |||
Name: | Xxxxxxxx X. Xxxxx | |||
Title: | President and Chief Executive Officer | |||
APCO, INC. |
||||
By: | /s/ Xxxxxxxx X. Xxxxx | |||
Name: | Xxxxxxxx X. Xxxxx | |||
Title: | President and Chief Executive Officer | |||
CORAM, INC. |
||||
By: | /s/ Xxxx X. Xxxxxxx | |||
Name: | Xxxx X. Xxxxxxx | |||
Title: | Chairman, President & CEO | |||
[Signature Page to Merger Agreement]